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ABSTRACT
INDUCTION OF CASPASE-DEPENDENT DEATH BY PROTEASOME
TARGETED THERAPY IN GLIOBLASTOMA
Christa Ann Manton, B.S.
Advisory Professor: Joya Chandra, Ph.D.
New therapeutic options are needed for glioblastoma, a deadly disease with a median
survival of only 14 months with current treatment. The proteasome inhibitor bortezomib
(BTZ) shows efficacy in cancers like myeloma, but its clinical utility in other cancer types
has been more limited. Newer proteasome inhibitors such as marizomib (MRZ) have unique
inhibitory and death inducing properties that have not been well examined in GBM.
Additionally, targeting other components of the ubiquitin-proteasome system is possible, but
has not been explored in GBM. Questions also still remain about the ability of BTZ and
MRZ to be delivered to brain tumors in a relevant orthotopic system. The goal of this study
was to determine the kinetics and mechanism of death induced by proteasome inhibitors in
GBM and to compare the ability of BTZ and MRZ to cause proteasome inhibition in
orthotopic brain tumors in order to establish a framework for the use of these drugs in the
clinic by identifying potential biomarkers of efficacy and enabling design of a combination
treatment strategy for potentiation of cell death in GBM. Using strategies that inhibited
multiple proteasome components, I determined that inhibition of the standard proteasome by
BTZ and MRZ was sufficient for optimal targeting of the ubiquitin-proteasome system in
GBM. I then determined that both BTZ and MRZ induced caspase-dependent death in GBM
cells that was dependent upon activation of caspase 9. Using an orthotopic xenograft model
of GBM, I found that both BTZ and MRZ increased levels of the proteasome substrates p21
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and p27 in intracranial tumors, with MRZ exerting slightly stronger effects, indicating that
these drugs do affect brain tumors. Examination of cleaved caspase 3 and lamin A as markers
of apoptosis in brain tumors from mice showed increased cell death after treatment with BTZ
or MRZ and the histone deacetylase inhibitor vorinostat. Together, this data clarifies the
optimal strategy for proteasome targeting in GBM, clarifies the hierarchy of caspase
induction by proteasome inhibitors, and provides evidence that proteasome inhibitors can
reach brain tumors where they exert functional effects and increase death in combination
with vorinostat.
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Chapter 1
Introduction: background, research plan, and relevance

1

1. Glioblastoma
Glioblastoma multiforme (GBM) includes brain tumors that arise de novo, as well as
astrocytomas that progress from lower grades to grade IV disease. GBM is the most common
type of malignant brain tumor, with an incidence of 3 cases per 100,000 person-years; studies
have also found a trend toward increased GBM incidence, though the reasons for this are
unclear [1, 2].
Before 2005, GBM was treated by surgical resection and radiation. Due to the
aggressive nature of this disease, the median survival of patients who received this treatment
was only 12 months [3]. The standard of care guidelines were expanded after promising
clinical trial results showed increased survival in GBM patients treated with radiation plus
temozolomide, an alkylating agent that causes DNA damage-induced cancer cell death [4].
Even with this improvement in treatment, however, the median survival of patients only
increased incrementally to 14.2 months (Fig. 1.1) [3, 4]. The continued poor prognosis of
GBM patients highlights the need for novel therapeutic strategies to enhance survival.
One of the largest efforts to understand GBM biology has been The Cancer Genome
Atlas Network, which first reported the full sequencing of 206 GBM samples in 2008 [5],
and expanded their analysis to include more than 500 GBM tumors in 2013 [6]. This
extensive sequence information allowed classification of GBM into 4 main molecular
subtypes: the proneural subtype, which is characterized by aberrations in platelet-derived
growth factor receptor alpha (PDGFRA), isocitrate dehydrogenase 1 (IDH1), and tumor
protein p53 (TP53); the classical subtype, which is characterized by aberrant epidermal
growth factor receptor (EGFR) expression; the mesenchymal subtype, with defects in
neurofibromin 1 (NF1) expression; and the neural subtype, which is associated with gene
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Figure 1.1: Poor survival of GBM patients
with or without temozolomide treatment.
Kaplan-Meier survival plot for GBM patients
treated between 2000-2003 (pre-temozolomide
era, median survival = 12 months) versus
2005-2008 (post-temozolomide era, median
survival = 14.2 months). Reprinted with
permission from Springer from Johnson DR,
O’Neill BP (2011) Glioblastoma survival in the
United States before and during the
temozolomide era. J Neurooncol 107:359–364
(License #3503270379443, Ref. [3]).
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signatures closer to more differentiated cells such as astrocytes and neurons [7]. Another
effort to pull together a large amount of data from sequencing of brain tumors is the
Repository of Molecular Brain Neoplasia Data (REMBRANDT), which includes data for
gene expression and clinical endpoints for over 800 samples from different kinds of brain
tumors [8].
Though these efforts have greatly contributed to our knowledge base about GBM,
more recent studies have indicated that these large scale sequencing efforts can greatly
underestimate the remarkable heterogeneity that occurs within individual GBM tumors.
Single cell studies identified subpopulations of cells within individual tumors that had a
single clonal origin, but had acquired expression of receptor tyrosine kinases from multiple
tumor subtypes, particularly of EGFR, MET, and PDGFRA [9, 10]. Expression of these
receptors was often mutually exclusive in the different subpopulations within the tumor.
Additionally, another study performed single cell RNA sequencing in multiple cells for 5
different primary GBM samples and found remarkable heterogeneity within single tumors
[11]. Notably, they identified cells that represented different subtypes (mesenchymal,
classical, proneural, and neural) within the same tumor.
This heterogeneity has important implications for therapeutic strategies, as it indicates
that targeting just one or even two of these abnormalities may not be effective. This is
highlighted by a phase I and II study that combined the EGFR inhibitor erlotinib with
temozolomide and radiation in newly diagnosed GBM patients [12]. Not only was there no
survival benefit in patients that received erlotinib, but specific analysis of the subset of
patients with EGFR amplifications showed that there was no significant survival advantage
in this subpopulation.
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The current body of knowledge emphasizes the complexity of GBM and highlights a
need for therapeutic strategies that can target broad mechanisms at work in cancer cells that
may have a variety of genetic mutations. One potential approach to this problem is targeting
the ubiquitin-proteasome system for GBM therapy.
2. The proteasome
The ubiquitin-proteasome system is responsible for the bulk of protein degradation in cells
(Fig. 1.2) [13]. The proteasome is in a key position to regulate many cellular pathways, as it
degrades misfolded and oxidatively damaged proteins [14], as well as key substrates
involved in processes such as cell cycle regulation [15] and cell death [16].
In this process, proteins are first marked for degradation by the addition of ubiquitin
chains in a series of steps that requires an E1 ubiquitin activating enzyme [17], an E2
ubiquitin-conjugating protein [18], and finally an E3 ubiquitin-protein ligase that recognizes
the specific protein to be degraded and transfers the ubiquitin to it [19, 20]. Polyubiquitin
chains form through attachment of the C-terminal glycine of one ubiquitin residue to a lysine
of the previous ubiquitin. [21]. Ubiquitin chains can form using several different linkages,
with chains attached at lysine 11 or 48 being most commonly associated with recognition and
degradation by the proteasome [22].
The proteasome was originally identified through purification experiments that
identified a high molecular weight protease complex that degraded proteins in an ATPdependent manner [23, 24]. Subsequent experiments revealed that the proteasome consists of
20S core particles paired with either one or two 19S regulatory particles that together form
the 26S proteasome [25, 26].
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Figure 1.2: Standard and alternative proteasome components. The
standard proteasome consists of 1 or 2 19S regulatory caps paired with a
20S catalytic core consisting of 2 outer “alpha” and 2 inner “beta”
heptameric rings. The beta subunits include the catalytic subunits, β1, β2,
and β5. These subunits can be substituted with β1i, β2i, and β5i to form the
immunoproteasome. Alternative cap subunits, such as caps composed of
PA28γ, can also be paired with catalytic cores. Proteins are degraded after
addition of a ubiquitin chain, which is recognized by the cap subunits.
Then, in an ATP-dependent process, proteins are deubiquitinated,
unwound, and fed into the 20S core where they are broken down into small
peptide chains.
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The 19S proteasome regulatory cap is a multisubunit complex that recognizes
ubiquitinated proteins, deubiquitinates them, and unwinds them in an ATP-dependent manner
[27, 28]. Proteins are then fed into the barrel-shaped 20S core particle. The core particle
consists of 4 heptameric rings: 2 outer “alpha” rings and 2 inner “beta” rings. The beta rings
contain the catalytic activities of the proteasome: the β1 subunit contains the caspase-like
activity, the β2 subunit contains the trypsin-like activity, and the β5 subunit contains the
chymotrypsin-like activity [29, 30]. These activities allow the proteasome to cleave
substrates after acidic, basic, and hydrophobic residues, respectively. Each β subunit contains
a nucleophilic N-terminal threonine residue that reacts with protein substrates [31].
Though the 19S caps and 20S core make up the “standard” proteasome, several
alternative proteasome components have also been described. In addition to 19S regulators,
proteasome core particles can also associate with PA28 regulators (also known as 11S
regulators), which change the core to a more open conformation and facilitate increased
production of antigens for presentation on class I major histocompatibility complexes [32,
33]. There are three PA28 subunits: PA28α and β, which are inducible by interferon-γ and
form heteroheptameric complexes, and PA28γ, which is not induced by interferon-γ and
forms a homoheptamer [32, 34]. Studies of the tissue distribution of various subunits have
found that the brain contains very low levels of PA28α and β, but very high levels of PA28γ
[35]. PA28γ has been shown to be able to facilitate degradation of cell cycle inhibitory
proteins, most notably including p21, in a ubiquitin-independent manner, indicating that it
has effects on key cellular functions [36].
The proteasome also has alternative catalytic subunits that are inducible by
interferon-γ and that make up what is known as the immunoproteasome, named because it
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increases production of antigens suitable for presentation on class I major histocompatibility
complex molecules [37, 38]. The immunoproteasome is characterized by incorporation of
LMP-7 (β5i), LMP-2 (β1i), and MECL-1 (β2i) into the 20S core particle and increased
cleavage after hydrophobic amino acids due to the specificity of both β1i and β5i for this
cleavage site [39]. Though immunoproteasome subunits are usually not expressed in normal
brain [35], immunohistochemical analysis revealed increased levels of immunoproteasome
subunits, particularly β1i and β5i, in a subset of GBM patient specimens [40].
3. Proteasome inhibitors
Inhibitors of the proteasome were originally developed as biological tools for
studying protein degradation and its role in muscle wasting [41]. There are 5 main classes of
proteasome inhibitors. Reversible inhibitors are classified as either peptide aldehydes (e.g.
MG132) or peptide boronates (e.g. bortezomib [BTZ]). Irreversible inhibitors can be divided
into β-lactones (e.g. marizomib [MRZ]), peptide vinyl sulfones, or peptide epoxyketones (e.g.
carfilzomib) [31]. Subsequent experiments revealed the potential of proteasome inhibition for
cancer therapy.
The most well-established, clinically utilized proteasome inhibitor is the dipeptide
boronic acid BTZ. Determination of the crystal structure of BTZ in complex with yeast 20S
proteasomes revealed that the boronic acid moiety of BTZ interacts with amino acids
surrounding the 20S proteasome active site threonine, forming a tetrahedral boronate adduct.
BTZ also forms a hydrogen bridge between a hydroxyl group from the boronate group and
the proteasome active site threonine itself [42]. Studies of the binding mechanism have
revealed that BTZ inhibits the proteasome in a manner that is slowly reversible. Crystal
structure experiments as well as a study that utilized a probe for the active sites of the
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proteasome revealed that, while BTZ has the strongest affinity for binding and inhibiting β5,
it can also inhibit β1 and β1i [42, 43].
Studies of BTZ have identified its anticancer potential in a variety of tumors
including colorectal cancer [44], pancreatic cancer [45, 46], and lung cancer [47]. BTZ has
been particularly successful in myeloma, as it induces death in multiple myeloma cells at
doses that are non-toxic to normal peripheral blood mononuclear cells, establishing it as a
potential therapeutic agent for this disease [48]. Subsequent clinical trials demonstrated
therapeutic activity of BTZ [49]. In the phase III Assessment of Proteasome Inhibition for
Extending Remissions (APEX) trial, BTZ increased median survival from 23.7 months in
patients receiving dexamethasone to 29.8 months [50]. Additionally, BTZ treatment was
associated with a 43% overall response rate and 9% complete response rate in the APEX trial.
Promising clinical trial results led to FDA approval of BTZ for relapsed or refractory
multiple myeloma [51, 52], and later for mantle cell lymphoma [53].
The success of BTZ fueled development of other inhibitors in this class, including
MRZ (formerly NPI-0052) [54, 55]. MRZ is a nonpeptide proteasome inhibitor that was
isolated from the marine actinomycete Salinispora tropica and structurally resembles the
natural proteasome inhibitor omuralide [56-58]. MRZ contains a β-lactone ring with a
chloride leaving group that is important for the irreversible inhibitory nature of MRZ; the
leaving group allows formation of a cyclic ether with the active site threonine in the
proteasome [59]. To study the importance of the chloride leaving group, MRZ analogs with a
leaving group (“LG” analogs) or without a leaving group (“non-LG” analogs) were
developed (Fig. 1.3). LG analogs caused sustained proteasome inhibition (>24 h), while nonLG analogs only inhibited the proteasome for short periods (≤12 h) [60]. A study in leukemia
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Figure 1.3: Reversible and irreversible analogs of MRZ. Examples of R-group
substitutions used to create irreversible NPI analogs with leaving groups (NPI-0052 [MRZ],
NPI-2151, and NPI-2150) and reversible NPI analogs without leaving groups (NPI-2063,
NPI-0047, and NPI-2080). Reprinted with permission from the American Society for
Pharmacology and Experimental Therapeutics from Obaidat A, Weiss J, Wahlgren B,
Manam RR, Macherla VR, Mcarthur K, Chao T-H, Palladino MA, Lloyd GK, Potts BC,
Enna SJ, Neuteboom STC, Hagenbuch B (2011) Proteasome regulator marizomib
(NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than
its reversible analogs. J Pharmacol Exp Ther 1–35 (Ref. [161]).

Figure 1.4: Structure and inhibitory function of BTZ and MRZ. A) Structure of the
proteasome inhibitors BTZ and MRZ (NPI-0052), which is structurally similar to
omuralide. The methylated C3 position of MRZ, which is one of the features that
distinguish it from omuralide, is circled. B-D) Determination of the inhibitory activity of
MRZ and BTZ on the chymotrypsin-like (B), caspase-like (C), and trypsin-like (D)
activities of proteasomes isolated from human erythrocytes. Reprinted with permission
from Elsevier Limited from Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar
M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom STC, Richardson P, Palladino MA, Anderson KC (2005) A novel orally
active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms
distinct from Bortezomib. Cancer Cell 8:407–419 (License #3503271470606, Ref. [62]).
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cells revealed increased cell death after treatment with the LG versus non-LG analogs [61].
In addition to causing more sustained proteasome inhibition compared to BTZ, MRZ also
inhibits the β5 and β2 proteasome subunits at lower doses than BTZ (Fig. 1.4) [62].
Differences in the mode of proteasome binding (irreversible for MRZ versus reversible for
BTZ) and target specificity (β5 and β2 for MRZ versus β5 and β1 for BTZ) have led to some
key differences in how these drugs induce death in cancer cells.
While BTZ and MRZ both target the “standard” 20S proteasome, specific inhibitors
of the immunoproteasome have also been developed. IPSI-001, a specific inhibitor of β1i,
induced death in myeloma cells and overcame resistance to BTZ [63]. ONX-0914 (also
called PR-957) is another immunoproteasome-specific inhibitor. It specifically targets LMP7
(β5i), and most current studies have focused on ability to attenuate immune-related diseases
such as arthritis and colitis [64, 65]. Future work targeting alternative proteasome
components in cancer is warranted.
4. Induction of apoptosis and autophagy by proteasome inhibitors in cancer
4.1 Apoptosis: activation of caspases
Proteasome inhibitors have been shown to induce caspase-dependent apoptosis in a variety of
cancer types, including leukemia and myeloma [66-68]. Apoptosis is carried out by a family
of cysteine proteases known as caspases. Caspases 2, 8, and 9 are initiator caspases; these
proteases exist as inactive pro-caspases that are activated in response to signals that induce
their recruitment to activation platforms and proteolytic processing of these caspases to their
active forms (Figure 1.5) [69]. Activation of initiator caspases is a multi-step process that
includes caspase dimerization, cleavage of the pro-domain, and cleavage to separate the
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Figure 1.5: Activation of initiator caspases. Caspase 2 is activated by recruitment
to the PIDDosome, caspase 8 is activated by death receptor signaling and recruitment
to the death-inducing signaling complex (DISC), and caspase 9 is activated after
release of cytochrome C from the mitochondria comes together with Apaf-1 to form
the apoptosome. Active initiator caspases activate executioner caspases. Activation of
apoptosis is antagonized by inhibitor of apoptosis proteins, including XIAP and
cIAP-1, which bind and inhibit active caspases. This inhibition of apoptosis is
released as Smac, an inhibitor of IAPs, is released from the mitochondria
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small and large subunits; active caspases consist of dimers with the large subunits on the
outside and the small subunits on the inside [70]. Each initiator caspase is activated in
response to unique cellular signals and initiates a cascade of events that leads to activation of
the effector caspases 3 and 7.
Caspase 8, which is part of the extrinsic apoptosis pathway, is activated in response to
binding of ligands such as Fas ligand or tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) to death receptors. Active death receptors then recruit caspase 8 to the deathinducing signaling complex for activation [69].
Caspase 9, which is part of the intrinsic apoptosis pathway, is activated downstream
of cytochrome C release from the mitochondria. The pro-apoptotic Bcl-2 family members
Bax and Bak form pores that facilitate release of cytochrome C from the mitochondria [71].
Cytochrome C then forms a complex known as the apoptosome with Apaf-1 and pro-caspase
9, facilitating activation of caspase 9 [72].
A third, less well-studied mode of caspase activation involves the initiator caspase 2.
Upon cellular stress, caspase 2 is recruited to and activated in a complex known as the
PIDDosome that consists of p53-induced protein with a death domain (PIDD) and RIPassociated ICH-1/CED-3-homologous protein with a death domain (RAIDD) [73]. It is then
thought to induce apoptosis by causing mitochondrial permeability and downstream
activation of caspase 9 in a manner that is dependent on cleavage of BID, a pro-apoptotic
Bcl-2 family member [74-76]. Caspase 2 has also been reported to act as a tumor suppressor,
as cells deficient in caspase 2 showed increased proliferation and defective cell cycle
checkpoint regulation in response to DNA damage [77].
Specific apoptotic studies in other cancer models have found that BTZ and MRZ rely
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on different caspases; MRZ induced caspase 8-dependent apoptosis in leukemia and
myeloma, while BTZ was more equally dependent on caspases 8 and 9 [62, 68]. Further
evidence that these inhibitors act by different mechanisms was provided by a study that
showed that MRZ can induce death in BTZ-resistant myeloma cells [62].
Studies have found that BTZ can induce death in GBM cells as measured by MTT
assay [78]. BTZ also induces cell cycle arrest and cleavage of poly ADP ribose polymerase
in GBM cells, suggesting that death may occur due to caspase activation and apoptosis but
without clarifying the role of specific caspases [79]. Preliminary evidence also suggests that
MRZ can induce death in glioma cells, but a more specific examination of the death
mechanism is lacking [80]. The dependence of proteasome inhibitors on activation of
specific initiator caspases has not yet been reported in GBM.
4.2 Increases in reactive oxygen species (ROS)
One stimulus for proteasome inhibitor-induced death is increased ROS levels after
proteasome inhibition. ROS, which are derived from oxygen molecules, include superoxides
(O2-), hydroxyl radicals (OH-) and hydrogen peroxide (H2O2). High levels of ROS are
capable of causing damage to many cellular components including DNA, proteins, and lipids.
Proteasome inhibitors have been shown to increase ROS in numerous types of cancer,
including multiple myeloma, mantle cell lymphoma, colon cancer, and lung cancer [47, 8184]. Inhibition of mitochondrial electron transport chain components prevented BTZ-induced
ROS increases, suggesting that ROS is likely produced by mitochondrial dysfunction, which
is also upstream of caspase 9 activation [47].
The importance of ROS was solidified by the fact that proteasome inhibitor-induced
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death in mantle cell lymphoma was blocked by treatment with the antioxidants glutathione
ethyl ester (GSHee) and N-acetyl cysteine, which acts as an antioxidant by increasing levels
of the antioxidant glutathione [82]. MRZ was also shown to cause ROS-dependent cell death
in leukemia [68]. Some studies have presented conflicting findings. One study showed that
lung cancer cells did not have increased ROS after BTZ treatment, and also were not
protected from BTZ-induced death by NAC [85], while a conflicting study reported that
induction of ROS and mitochondrial dysfunction were important events in BTZ-mediated
apoptosis in lung cancer cells [47]. These results suggest that effects on ROS and the
protective effect of antioxidants may be cell-specific, possibly due to factors such as
differences in basal antioxidant capacity in different cell types.
4.3 Stimulation of autophagy
Another pathway of cellular protein breakdown is autophagy, a process in which
proteins and organelles are first engulfed by autophagosomes, followed by degradation in
lysosomes. The role of autophagy in cancer and therapeutics is complex: autophagy can aid
survival by clearing cells of damaged proteins and aggregates, but may also promote death
when stimulated at high levels [86]. Proteasome inhibitors have been found to induce
autophagy in a variety of cell types including prostate cancer [87] and melanoma [88].
Induction of autophagy is generally thought to be a protective mechanism in cancer cells
treated with proteasome inhibitors, and dual inhibition of the proteasome and autophagy has
been shown to increase cell death [87, 89]. Increased death after dual inhibition of the
proteasome and autophagy appears to be specific to transformed cells, possibly indicating an
increased reliance of cancer cells on these cellular processes [90]. Though it is possible that
autophagy may also be responsible for cell death in some cases [91], careful studies are
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necessary to delineate whether this process is acting as a pro-death or pro-survival
mechanism.
5. Clinical challenges to treatment of GBM with proteasome inhibitors
5.1 The Blood Brain Barrier (BBB)
The BBB is formed by association among the endothelial cells that form capillaries in
the brain, pericytes, and astrocyte endfeet (Fig. 1.6) [92]. Together, these cells form a barrier
that serves many functions, including restriction of the substances that are able to exit the
capillaries in the brain. The BBB is therefore thought to prevent some therapeutic agents
from being effectively delivered to lesions in the brain. Though there is evidence that brain
tumors disrupt the BBB [93], enhancing delivery of various therapeutics, it is still important
to ensure that drugs are able to effectively reach brain tumors.
The BBB may partially explain why, despite results indicating that BTZ causes death
in GBM cells in vitro, results in vivo have been mixed. One study in an orthotopic xenograft
model of GBM investigated BTZ in combination with neural stem cells (NSCs) expressing
TRAIL [94]. NSCs have been shown to migrate to intracranial tumors, and expression of
TRAIL allows them to trigger death receptors on cancer cells. This study found that BTZ
increased 100-day survival by 20% in mice also receiving NSC-TRAIL. However, strong in
vitro data showing the efficacy of the combination of BTZ and the histone deacetylase
inhibitor (HDACi) vorinostat [95, 96] did not translate in a clinical trial; a phase II study of
BTZ and the HDACi vorinostat in relapsed GBM patients was closed at the interim analysis
due to failure to prevent disease progression [97]. This clinical trial did not include molecular
markers of efficacy, such as analysis of proteasome substrates or histone acetylation, to
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Figure 1.6: Structure of the blood brain
barrier. The blood brain barrier is formed from
the endothelial cells that form capillaries in the
brain, along with pericytes and astrocyte
endfeet. Microglia are the immunocompetent
cells in the brain. Reprinted with permission
from Elsevier Limited from Abbott NJ,
Patabendige AAK, Dolman DEM, Yusof SR,
Begley DJ (2010) Structure and function of the
blood-brain barrier. Neurobiol Dis 37:13–25
(License #3503280146440, Ref. [92]).
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indicate whether the drugs were successfully affecting their targets in the brain tumors at the
doses and treatment schedules used.
Additionally, subcutaneous models are frequently used for in vivo GBM studies, and
these experiments do not answer questions about delivery of agents to orthotopic tumor sites
[80, 98]. BTZ did increase the efficacy of NSC-TRAIL therapy in orthotopic brain tumors,
but specific markers of proteasome inhibition were not reported in this study, so there was no
direct measurement of proteasome inhibition [94]. For MRZ, a previous report examined
proteasome activity in mice 10 min to 24 h following intravenous injection of 0.15 mg/kg
MRZ and reported that MRZ did not decrease proteasome activity in the brain; however, this
study was performed in mice without brain tumors, and therefore with intact BBB [54, 99].
Therefore, the current body of evidence concerning the extent of proteasome inhibition
achieved by BTZ and MRZ in relevant orthotopic brain tumor models is incomplete.
5.2 Adverse Effects
Between 33% and 66% of myeloma patients treated with BTZ experience peripheral
neuropathy [100]. Though the incidence of peripheral neuropathy tends to be lower in
patients with solid tumors treated with BTZ [101], it is still an important consideration for
patients. Treatment with antioxidants such as Vitamin E, NAC, and glutathione have
produced promising results for decreasing peripheral neuropathy [102, 103]. However,
supplementation with antioxidants must be implemented with caution. Studies have shown
that Vitamin C can directly inactivate BTZ, reducing its efficacy [85]. Additionally, given
previous reports that ROS production is important for the mechanism of death following
proteasome inhibition, it is important to make sure that any antioxidant used clinically
reduces adverse effects while not diminishing the efficacy of proteasome inhibition. Notably,
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a phase I trial in myeloma indicated that MRZ was not associated with peripheral neuropathy
[104].
5.3 Drug Resistance
Though BTZ does achieve responses in the clinic, some patients do not respond, and many
patients treated with BTZ eventually do relapse [50]. Several mechanisms of BTZ resistance
have been described. In some cases, cells induce changes to the proteasome itself; this may
include up-regulation of proteasome subunits, alterations in the composition of the
proteasome subunit pool, or mutations that limit binding of BTZ [105, 106]. For these cases,
resistance may be overcome by new-generation proteasome inhibitors such as MRZ, which
targets the proteasome at lower concentrations and induces death by mechanisms different
from BTZ, or immunoproteasome inhibitors, which target alternative catalytic subunits [6264, 107, 108].
In other cases, resistance occurs due to differences in the cellular environment that
attenuate the toxic functions of proteasome inhibition. For example, cells with a higher basal
antioxidant capacity, such as elevated expression of the antioxidant transcription factor Nrf2,
have been found to be more resistant to proteasome inhibitors [109, 110]. Also, activation of
autophagy, an alternative cellular degradation pathway, was found to protect cells from
proteasome inhibitors in prostate cancer [111]. Together, these studies indicate that cells may
have ways of escaping the toxic effects of proteasome inhibitors by modulating the cellular
environment and inducing alternative pathways for protein disposal.
Another route of resistance involves direct inhibition of apoptosis pathways.
Overexpression of anti-apoptotic regulators of mitochondrial integrity such as Bcl-2 and BclXL is seen in some types of cancer, including GBM, which could make these cells resistant
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to therapies that target the intrinsic pathway of apoptosis [112]. Targeting Bcl-2 and Bcl-XL
induces apoptosis in GBM cell lines, suggesting these proteins are important mediators of
apoptosis in GBM [113].
Another class of proteins involved in death regulation is the inhibitor of apoptosis
protein (IAP) family, which includes several proteins that directly bind and inhibit caspases.
This family includes X-linked IAP (XIAP), cIAP-1, and cIAP-2, which inhibit caspases 3, 7,
and 9, as well as other members such as survivin, which inhibits caspases 3 and 7 [114]. IAPs
bind to caspases through baculovirus inhibitory repeat (BIR) domains, and several family
members possess ubiquitin ligase activity which can be used to target caspases for
degradation [115]. Upregulation of IAP expression has been documented in several cancer
types, including lung cancer, prostate cancer, and leukemia, and several studies have found
links between IAP expression and poor patient outcomes [116-118]. Members of the IAP
family have been found to be upregulated in GBM, with XIAP, cIAP-1, cIAP-2, and survivin
being expressed at high levels on CD133+ putative GBM stem cells [112, 119, 120]. In cells,
second mitochondria-derived activator of caspases (Smac) is an inhibitor of IAPs. Smac is
normally sequestered in the mitochondria, but is released along with cytochrome C upon
activation of apoptosis. Smac then binds to the BIR domains of IAPs, preventing interactions
between IAPs and caspases, and also antagonizing the ubiquitin ligase activity of IAPs [121,
122]. Therapeutic agents have been developed that mimic the activity of Smac. Birinapant
and LCL-161 bind to the BIR domains of XIAP, cIAP-1 and cIAP-2 [123, 124]. Smac
mimetics have been shown to sensitize GBM cells to multiple therapeutics including PDGFR
inhibition [125], TRAIL [126], and radiation [127]. This suggests that IAPs may play a part
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in making GBM cells resistant to apoptosis, and targeting them may be a strategy for
overcoming resistance to apoptosis-inducing agents such as proteasome inhibitors.
5.4 Need for Combination Treatment Strategies
To maximize therapeutic efficacy and limit toxicity, many drugs used in the clinic are
administered as part of rationally designed combination strategies. MRZ and BTZ are both
good candidates for combination therapy strategies. An improved understanding of how BTZ
and MRZ induce GBM cell death will aid in the design of rational combination strategies that
potentiate the efficacy of these agents in the clinic.
One combination strategy that has been investigated in other cancer types is that of
proteasome inhibitors with HDACi. In cells, DNA is packaged around a core octamer of
histones. Modifications, such as acetylation, ubiquitin, and methylation, to the tail sections of
these histone proteins affects how tightly the DNA is packaged, and therefore impacts gene
expression. Acetylation of histone tails is regulated by two types of enzymes: histone
acetyltransferases (HATs) that add acetyl groups to histone tails, and histone deacetylases
(HDACs) that remove acetyl groups. By removing acetyl groups, HDACs lead to a more
closed, transcriptionally repressed DNA conformation [128]. Expression of HDACs has been
shown to be altered in several types of cancer, including GBM [129, 130].
The first clinically relevant HDACi was the hydroxamic acid vorinostat (also called
SAHA) [131]. There are four classes of HDACs, and vorinostat inhibits classes I and II.
Vorinostat leads to accumulation of acetylated histones, and alters expression of 2–10% of
genes in transformed cells [132].
Vorinostat induces death in a variety of cancer types, and it is FDA-approval for
cutaneous T-cell lymphoma [133-135]. Several other HDACi have been developed. Some
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HDACi have more narrow inhibitory profiles, such as the benzamide derivative entinostat, a
specific inhibitor of class I HDACs [136]. Alternatively, other HDACi have more broad
inhibitory capacity; the hydroxamic acid panobinostat inhibits HDACs 1, 2, 3, 4, 6, 7, 8, and
9 at lower concentrations than vorinostat [137]. Panobinostat is currently in several clinical
trials, including a phase I/II trial in combination with the angiogenesis inhibitor bevacizumab
for malignant glioma [138].
Past studies have indicated the efficacy of the combination of HDACi with
proteasome inhibitors. In leukemia, MRZ induced synergistic cell death that was dependent
on ROS and caspase 8 activation in combination with the HDACi entinostat and valproic
acid [68]. Miller et al. also reported that the HDACi vorinostat and entinostat decreased
mRNA levels of all three proteasome catalytic subunits, and MRZ, but not BTZ, increased
acetylation of histone H3 on its own in leukemia [139]. These results suggest that there is
overlap between the mechanisms of HDACi and proteasome inhibitors that may contribute to
their synergistic effects in combination. Combinations of these classes of agents are currently
in clinical trials for multiple cancer types (Table 1.1).
A study in GBM cells found that BTZ and vorinostat synergistically induced death
that was dependent on ROS and mitochondrial dysfunction [96]. Therefore, the combination
of proteasome inhibitors and HDACi may be a potent combination in GBM. Though there
was a clinical trial of BTZ and vorinostat in relapsed GBM patients that did not prevent
progression [97], this study did not report molecular markers of drug delivery and efficacy.
Therefore, future studies with combinations of HDACi and proteasome inhibitors in GBM
should focus on molecular markers of drug efficacy and comparisons of efficacy between
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Proteasome
Inhibitor
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bortezomib

panobinostat

bortezomib

Additional
agents

vorinostat
AMG 655

sorafenib

marizomib

vorinostat

Trial
Phase

Disease

I/II & III

multiple myeloma

II

T-cell lymphoma

I

mantle cell lymphoma

III

multiple myeloma

I

lymphoma

II

non-Hodgkin lymphoma

I/II

acute myeloid leukemia

II

soft tissue sarcoma

II

mantle cell lymphoma
and diffuse large cell
lymphoma

I

pediatric central nervous
system tumors and
lymphoma

II

non-small cell lung
cancer

II

glioblastoma

I

non-small cell lung
cancer, pancreatic cancer,
melanoma, lymphoma,
and multiple myeloma

Table 1.1: Clinical trials with proteasome inhibitors and HDACi. A selection
of the clinical trials that include the proteasome inhibitors BTZ or MRZ with the
HDACi vorinostat or panobinostat currently registered at ClinicalTrials.gov.
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clinically established drugs such as BTZ and vorinostat and newer-generation inhibitors such
as MRZ and panobinostat.
6. Research Plan
Past in vitro and clinical experience with BTZ has highlighted important needs in 3
avenues of research: 1) evaluation of next-generation proteasome inhibitors like MRZ and
immunoproteasome inhibitors, which may have differences in delivery to brain tumors,
inhibitory action, and mechanism of death induction that could make them more effective
clinically; 2) determination of cellular events that are necessary for proteasome inhibitor
efficacy that can help anticipate drug resistance and serve as biomarkers of drug function;
and 3) in vivo evaluation of the ability of proteasome inhibitors to reach brain tumors and
exert function effects as part of combination therapy regimens in relevant orthotopic models.
Based on these questions, my central hypothesis was that determination of the mechanism of
death induced by proteasome inhibitors and comparison of the ability of BTZ and MRZ to
cause proteasome inhibition in orthotopic brain tumors would establish a framework for the
use of these drugs in the clinic by identifying potential biomarkers of efficacy and enabling
design of a combination treatment strategy for potentiation of cell death in GBM.
To address this hypothesis, I first performed a time course and dose-response analysis
of the kinetics of proteasome inhibition and death induction following treatment of GBM cell
lines with BTZ and MRZ, alone or in combination with specific inhibitors of the
immunoproteasome or the alternative cap subunit PA28γ. After determining that targeting the
proteasome with BTZ and MRZ effectively induced death in GBM, I characterized the
mechanism of caspase activation in these cells.
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Careful time course analysis of initiator caspases 2, 8, and 9 was performed, as well
as monitoring of caspase 3/7 activity. Treatment with a pan-caspase inhibitor, as well as
specific chemical inhibitors and shRNA blockade of caspases 2, 8, and 9, were used to
establish the role of specific caspase pathways in GBM cells after proteasome inhibition. The
role of ROS in proteasome inhibitor-mediated death was also examined using the reducing
agents DTT and NAC, as well as direct introduction of the antioxidant GSH. The ability of
these agents to block caspase activation and death was determined.
These experiments revealed an important role for caspase 9 in proteasome inhibitorinduced death in GBM cells. Therefore, I determined whether combinations of BTZ and
MRZ with the HDACi potentiated caspase 9 activation and death. After thorough
examination of the synergistic potential of proteasome inhibitors plus HDACi in GBM cell
lines, I used an orthotopic xenograft model of GBM to establish the ability of proteasome
inhibitors to cause proteasome substrate accumulation in brain tumors, and also to induce
molecular markers of apoptosis when administered in combination with vorinostat.
Together, these data explore important questions about the most effective strategy for
targeting the proteasome in GBM, the mechanism of death induction by proteasome
inhibitors, and the in vivo potential of BTZ and MRZ in a therapeutic combination that
potentiates their mechanism of death induction.
7. Importance to the Area of Cancer Research
BTZ has been shown to effectively target the proteasome and induce death in cancers
such as myeloma and mantle cell lymphoma [52, 53]. However, there are still many
unanswered questions about the potential of ubiquitin-proteasome system targeting in GBM.
This study provides an examination of a few of these key questions. First, examination of the
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efficacy of targeting particular proteasome components, including the standard catalytic
subunits with BTZ and MRZ, as well as immunoproteasome subunits and PA28γ, utilized
current innovations in the field of proteasome inhibitors to determine which subunits should
be targeted for the most effective therapeutic strategy for GBM. Secondly, this study
elucidated the mechanism of caspase activation in GBM cells after proteasome inhibition by
BTZ and MRZ, and found it to be dependent upon caspase 9. This information is useful for
establishing biomarkers of drug efficacy as well as anticipating mechanisms of resistance.
Finally, this study provides in vivo evaluation of the ability of BTZ and MRZ to inhibit the
proteasome in orthotopic brain tumors, and examines the potential of the clinically relevant
combination of proteasome inhibitors and HDACi both in vitro and in vivo. Together, this
study provides an evaluation of several aspects of proteasome inhibitor function that will
help establish their clinical potential and strategies for their therapeutic use.
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Chapter 2
Kinetics of proteasome inhibition by BTZ and MRZ, and targeting of alternative proteasome
components, in GBM.
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Specific Aim 1: Examine the kinetics of proteasome inhibition by the inhibitors BTZ
and MRZ, as well as by methods targeting alternative proteasome components.

In this chapter, I examined the kinetics of proteasome inhibition following treatment
of GBM cells with the proteasome inhibitors BTZ and MRZ, and also explored strategies for
targeting other proteasome components. The ability of therapeutic agents to cause sustained
proteasome inhibition has been linked to their ability to induce cell death [61]. Additionally,
BTZ and MRZ target proteasome catalytic subunits with different affinities and can induce
death by different mechanisms in multiple myeloma [62], suggesting that targeting of
different proteasome components may enhance cell death. Therefore, I hypothesized that the
irreversible nature of MRZ would result in more sustained proteasome inhibition compared
to the reversible agent BTZ, and that targeting multiple proteasome components would have
the largest impact on cell death in GBM.
Proteasome activity was examined in time course experiments after treatment of
whole cells or cell lysates with the standard proteasome inhibitors BTZ and MRZ, either
continuously or after brief drug pulse exposure. I also examined the role of drug efflux on
proteasome inhibitor efficacy by using verapamil to block drug efflux, and used analogs of
MRZ to explore the importance of irreversible versus reversible proteasome inhibition.
Based on the previous observation that immunoproteasome subunits were upregulated
in immunohistochemistry analysis of GBM tumors specimens [40], the role of the
immunoproteasome in GBM was explored. The REMBRANDT database was mined for
information about immunoproteasome subunit expression and correlations with disease
outcomes. A specific inhibitor of the immunoproteasome, ONX-0914, was used to examine
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the importance of the immunoproteasome to GBM cell survival, and the possibility that
combined targeting of standard and immunoproteasomes could be beneficial in GBM.
Lastly, PA28γ, which forms an alternative regulatory cap, was considered as a
potential proteasome target for GBM therapy based on the fact that PA28γ is enriched in the
brain [35]. Together, the data in this chapter characterizes the kinetics of standard
proteasome inhibition by BTZ and MRZ and explores targeting of alternative proteasome
subunits in order to establish the most effective strategy for targeting the proteasome in
GBM.
BTZ causes longer-lasting inhibition of the proteasome than MRZ in GBM cells.
To examine the kinetics of proteasome inhibition following treatment with BTZ and
MRZ, a panel of GBM cell lines was treated with these agents for periods of time ranging
from 2 h to 48 h. Chymotrypsin-like (CT-L) activity, which is the activity of the β5 subunit
that is targeted by both BTZ and MRZ, was measured by incubating treated cells with the
fluorogenic substrate suc-LLVY-amc. In LN18 cells, both BTZ and MRZ caused strong
initial inhibition of the proteasome at 2 h. MRZ-treated cells began to recover proteasome
activity 16 h after treatment, while BTZ caused more sustained inhibition (Fig. 2.1A). A
similar trend was observed in 2 other GBM cell lines, U251 and U87, with strong initial
inhibition (2 h) after treatment with both BTZ and MRZ, but with proteasome recovery
occurring between 16 and 24 h in cells treated with MRZ (Fig. 2.1B).
The other 2 catalytic activities of the proteasome were also examined using the
fluorogenic substrates z-LLE-amc for caspase-like proteasome activity (Fig. 2.2A) and bocLRR-amc for trypsin-like activity (Fig. 2.2B). Both BTZ and MRZ caused decreases in
caspase-like activity. Similar to the CT-L activity, caspase-like activity recovered slightly
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Figure 2.1: Inhibition of chymotrypsin-like proteasome activity by MRZ and BTZ in
GBM cells. A) Chymotrypsin-like (CT-L) proteasome activity in LN18 cells treated with 75
nM MRZ or BTZ for increasing periods of time measured using the fluorogenic substrate
suc-LLVY-amc (*p < 0.05). B) CT-L proteasome activity in U87 and U251 cells treated with
75 nM MRZ or BTZ for 2, 16, or 24 h (*p < 0.05 compared to MRZ).
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Figure 2.2: Inhibition of caspase-like and trypsin-like proteasome activity by MRZ and
BTZ in GBM cells. A) Caspase-like proteasome activity in LN18 cells treated with 100 nM
proteasome inhibitors measured using the fluorogenic substrate z-LLE-amc (*p < 0.05). B)
Trypsin-like proteasome activity in LN18 cells treated with 100 nM proteasome inhibitors
measured using the fluorogenic substrate boc-LRR-amc (*p < 0.05).
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16 h after MRZ, but not BTZ, treatment. Both drugs had only slight effects on trypsin-like
activity, with BTZ inducing a greater decrease in activity at 24 h.
To confirm that the changes in proteasome activity that I observed were translating
into functional effects in cells, I examined levels of ubiquitin and the proteasome substrate
p27, both of which should accumulate after proteasome inhibition. LN18 cells were treated
for 4 h and 16 h with doses of BTZ and MRZ that were found to cause DNA fragmentation
in 50% of cells (290 nM MRZ and 15 nM BTZ; see Chapter 3, Fig. 3.2). Lysates were then
probed for ubiquitin and p27 (Fig. 2.3). Ubiquitin accumulation occurred at both 4 h and 16
h, and accumulation of p27 was observed at 16 h. This confirms that the proteasome
inhibitors decreased proteasome activity and caused accumulation of proteasome substrates.
The time courses of proteasome inhibition indicated that proteasome activity
recovered in cells treated with MRZ, while BTZ led to more sustained decreases in activity.
This was unexpected given the fact that MRZ is an irreversible inhibitor, while BTZ is
slowly reversible, which should mean that MRZ causes more sustained inhibition of the
proteasome. To see whether the increased proteasome activity in MRZ-treated cells was
associated with compensatory upregulation of proteasome subunit expression, protein levels
of the catalytic subunit β5 (PSMB5) were examined by Western blot (Fig. 2.4). Levels of β5
were unchanged from 1 h to 24 h following treatment with either BTZ or MRZ. To further
examine this phenomenon, I evaluated whether drug efflux or differences in the ability of the
inhibitors to bind proteasomes could explain the recovery of activity in MRZ-treated cells.
To examine efflux, I used verapamil, an inhibitor of the P-glycoprotein efflux pump
that has been shown to reverse efflux-mediated chemotherapy resistance [140]. LN18 cells
were pre-treated for 30 min with verapamil, followed by 48 h treatment with MRZ, BTZ, or
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Figure 2.4: Levels of proteasome subunit β5 after treatment with
proteasome inhibitors. Lysates from LN18 cells treated for various
times with DMSO (D), 100 nM MRZ (M) or 100 nM BTZ (B) were
probed for protein expression of the proteasome subunit β5.
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the known P-glycoprotein substrate bis-chloroethylnitrosourea (BCNU). After treatment,
DNA fragmentation was analyzed by flow cytometric analysis of cells stained with
propidium iodide; the subdiploid population was gated for the analysis. By this method, I
found that verapamil did increase the amount of DNA damage caused by BCNU, indicating
that verapamil blocked BCNU efflux. However, verapamil pre-treatment did not significantly
enhance DNA fragmentation in cells treated with either MRZ or BTZ (Fig. 2.5). This
indicates that efflux in this manner is not a major mechanism that attenuates the effect of
these drugs.
Next, I examined the proteasome binding ability of these drugs in cellular lysates.
LN18 cells were lysed by freezing and thawing on dry ice in 20S proteasome lysis buffer
(described for proteasome activity assay in the Methods section), which is a gentle lysis that
keeps proteasome core particles intact. Lysates were then incubated for 1, 4, or 24 h with
BTZ and MRZ. In the lysates, both BTZ and MRZ caused sustained proteasome inhibition
with nearly identical kinetics (Fig. 2.6). Notably, there was no recovery of proteasome
activity in MRZ-treated cell lysates.
Together, this data indicates that both BTZ and MRZ have equal capacity for
proteasome inhibition in cell lysates, and that efflux through P-glycoprotein does not
significantly attenuate either drug. Therefore, it is possible that MRZ is modified or
metabolized in the whole cell environment in a way that prevents it from having a sustained
effect on proteasomes. This could involve modifications that inactivate MRZ or drug
breakdown.
To further examine the kinetics of proteasome inhibition by BTZ and MRZ, I also
examined inhibition of proteasome activity and induction of death caused by brief exposure
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Figure 2.5: Drug efflux through P-glycoprotein does not affect proteasome
inhibitor efficacy. LN18 cells were pre-treated for 30 min with verapamil,
followed by treatment with proteasome inhibitors or the known P-glycoprotein
substrate BCNU for 48 h. Cells were stained with propidium iodide, and DNA
fragmentation was assessed.
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cell lysates. LN18 cells lysed in 20S proteasome lysis buffer were plated in a 96-well
plate. They were then treated with varying concentrations of proteasome inhibitors,
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were not significant (p > 0.05).
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of cells to proteasome inhibitors. It is likely that pulse treatment of cells, followed by drug
washout, more closely resembles the way the drugs work in vivo than a continuous treatment
model. The ability of a short exposure time to cause sustained effects could be important for
in vivo efficacy. LN18 cells were treated for various lengths of time with proteasome
inhibitors: 2, 4, 6, 8, 16, or 24 h (Fig. 2.7A). The treatment time indicated in Fig. 2.7A
represents the time of drug exposure. After that time, the media with the drug was aspirated,
wells were washed 2X with PBS, and fresh media was added to each well for the remaining
time until 24 h total. For example, the “2 h” cells were treated with proteasome inhibitors for
2 h, then the drug was washed out and replaced with fresh media for an additional 22 h
before harvesting and assessment of proteasome activity. Using this method, I found that all
exposure times (2–24 h) caused similar levels of proteasome inhibition for MRZ, indicating a
potent effect even after short pulse treatment. However, longer BTZ treatment times led to
progressively greater degrees of proteasome inhibition. Treatment with BTZ for around 8 h
was required to achieve the levels of inhibition seen with MRZ after 2 h. This indicates that
MRZ is a more effective agent for short exposure times.
The effects on proteasome inhibition were mirrored in the results for cell death after
washout treatment. For analysis of death, cells were treated for indicated times, then fresh
media was added until cells reached a total incubation time of 48 h. MRZ caused similar
levels of DNA fragmentation in cells treated for 2 to 24 h, while BTZ caused increasing
amounts of DNA fragmentation with longer exposure times (Fig. 2.7B). Notably, BTZ is
capable of causing slightly greater levels of DNA fragmentation overall, but requires longer
exposure times than MRZ to cause significant death. Therefore, while BTZ is the more
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Figure 2.7: MRZ causes stronger proteasome inhibition and more DNA fragmentation
than BTZ after short pulse treatments. A) LN18 cells treated with 100 nM proteasome
inhibitors for 2–24 h. After indicated time of treatment, drug was removed and fresh media
was added to wells. CT-L activity was assessed after a total time of 24 h (treatment + postwashout) for all samples. B) LN18 cells were treated with 100 nM proteasome inhibitors for
indicated times, following which drug was removed and fresh media was added to wells.
After a total time of 48 h, DNA fragmentation was assessed by propidium iodide staining.
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potent inhibitor under continuous conditions, MRZ may be more effective in a washout
system that more closely mirrors clinical conditions.
The long-lasting proteasome inhibition caused by MRZ in other model systems has
generally been attributed to its properties as an irreversible inhibitor, which is due to the
presence of a chloride leaving group. To further study the mechanism of MRZ, several
analogs of MRZ were developed that either have leaving groups (LG analogs) or do not have
leaving groups (non-LG analogs) [60]. Studies have found that the LG analogs do in fact
cause longer lasting proteasome inhibition and greater cell death in leukemia [61]. Since
GBM cells continuously treated with MRZ recover proteasome activity, I used the LG and
non-LG analogs to see if the irreversible nature of MRZ was still distinguishable from nonLG analogs. Preliminary experiments with MRZ analogs indicated that the LG analogs,
including MRZ, did cause stronger proteasome inhibition that was more sustained (at 24 h)
compared to the group of non-LG analogs in LN18 cells (Fig. 2.8A). While the LG analogs
had some recovery of proteasome activity at 24 h, it was less pronounced than the recovery
observed with non-LG analogs. LN18 cells were also examined for viability by trypan blue
exclusion after 48 h of treatment. In this case, the LG-analogs caused decreases in viability,
while the non-LG analogs did not (Fig. 2.8B). This data demonstrates that there are clear
differences between the irreversible (LG) and reversible (non-LG) analogs of MRZ in GBM
cells. Interestingly, BTZ acted more similarly to the irreversible analogs than the reversible
analogs both in terms of sustained proteasome inhibition and induction of death (Fig. 2.8AB).
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Figure 2.8: Effects of reversible and irreversible MRZ analogs. A) CT-L activity in
LN18 cells treated for 2 or 24 h with 10 nM BTZ or 100 nM MRZ and its analogs. B)
1
Viability measured by trypan blue exclusion in LN18 cells treated for 48 h with 10 nM BTZ
or 100 nM MRZ and its analogs. (LG = leaving group).
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Immunoproteasome expression, correlation with survival, and specific targeting in
GBM.
Though immunoproteasome subunits are not highly expressed in normal brain, a past
report indicated upregulation of these proteins in a subset of GBM patient specimens by IHC
[40]. The immunoproteasome has a distinct profile of protein cleavage characterized by
increased cleavage after hydrophobic residues [39] and has also been shown to be important
for degradation of oxidatively damaged proteins [141]. Therefore, the immunoproteasome
could be an interesting new target in GBM cells.
I first examined expression of the immunoproteasome subunit LMP7 (β5i) in a panel
of GBM cells as well as a normal human astrocyte line that was immortalized using the
human papilloma virus genes E6/E7 and telomerase reverse transcriptase. I observed variable
levels of LMP7 protein expression in the GBM panel (Fig. 2.9A). I also mined data from the
REMBRANDT database and found that levels of immunoproteasome subunit gene
expression was increased in the set of 228 GBM specimens compared to 28 non-tumor
controls, particularly for β1i and β5i (Fig. 2.9B). Expression of β5i also correlated with
glioma patient outcomes (Fig. 2.10). Patients with up-regulation of β5i had significantly
shorter survival times compared to patients with down-regulation. Together, this information
establishes the immunoproteasome as a potential therapeutic target in GBM.
To explore the role of the immunoproteasome in GBM, I obtained the specific
immunoproteasome inhibitor ONX-0914 (formerly PR-957). I first treated GBM cells with
pulse treatment of ONX-0914, followed by drug washout and examination of DNA
fragmentation after a total of 48 h. I found that GBM cells were fairly resistant to ONX-0914,
with less than 30% DNA fragmentation seen after the longest pulse treatment (24 h) in both
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LN18 and SNB19 cells (Fig. 2.11A). To further test the potential of ONX-0914, I examined
DNA fragmentation after continuous treatment with increasing doses of the drug (500 nM–
1.5 µM) in U87, LN18, U251, and SNB19 GBM cells. Even with continuous treatment, high
doses of ONX-0914 caused only minor increases in DNA fragmentation. Notably, the
expression level of β5i did not correlate with sensitivity, as U251 cells had the highest
expression level (Fig. 2.9A), but were not sensitive to ONX-0914.
To ensure that I was achieving complete and selective inhibition of β5i, I performed
experiments in collaboration with Onyx Pharmaceuticals. They have developed an enzymelinked immunosorbent assay (ELISA)-based method for determining specific inhibition of
each proteasome and immunoproteasome subunit in cell lysates [142]. Using this method, I
was able to assess specific proteasome inhibition of β5 versus β5i. A low, 250 nM dose of
ONX-0914 caused nearly complete inhibition of LMP7 after 1 h and 24 h of treatment in
LN18 cells, while causing minimal inhibition of β5 (Fig. 2.12). The 1.5 µM dose of ONX0914 also had significant effects on β5, especially after 24 h of treatment. This indicates that
the 250 nM dose of ONX-0914 is sufficient to cause complete inhibition of β5i, while the 1.5
µM dose is less specific. Since the higher dose of ONX-0914 was required to induce DNA
fragmentation (Fig. 2.11B), this suggests that specific inhibition of the immunoproteasome
itself is insufficient to cause DNA fragmentation in GBM cells.
This is perhaps unsurprising, as the proteasome pool in cells likely contains both
standard and immunoproteasomes, and targeting them both in combination may be a more
effective strategy. Therefore, I tested combinations of the standard proteasome inhibitors
BTZ and MRZ in combination with ONX-0914 at doses that were selective for the
immunoproteasome. Combining these agents did not cause strong increases in DNA
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fragmentation (Fig. 2.13), indicating that this combination did not lead to strong potentiation
of cell death in GBM lines.
Targeting PA28γ in GBM.
Studies have also found that the proteasome regulatory subunit PA28γ is highly
expressed in the brain [35]. To examine whether PA28γ affected sensitivity to proteasome
inhibitors, I compared the sensitivity of wild-type mouse embryonic fibroblasts (MEFs) to
PA28γ-/- MEFs. After 48 h of treatment with BTZ and MRZ, I examined DNA fragmentation
and found that PA28γ-/- MEFs showed similar sensitivity as wild-type MEFs to both BTZ
and MRZ (Fig. 2.14A).
To determine whether PA28γ played a unique role in GBM, I first examined PA28γ
expression in a panel of GBM cell lines and found that it was expressed, though at varying
levels (Fig. 2.14B). To test whether PA28γ impacted the sensitivity of GBM cells to
proteasome inhibition, I first knocked down PA28γ in LN18 cells using transient transfection
of siRNA (Fig. 2.14C). After establishing knockdown, I treated these cells with proteasome
inhibitors. Knockdown of PA28γ did not significantly alter the sensitivity of LN18 cells to
BTZ or MRZ (Fig. 2.14D). Therefore, it appears that inhibition of the proteasome catalytic
activities with BTZ or MRZ is not greatly potentiated when combined with knockdown of
PA28γ.
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Summary
In this chapter, I performed a detailed analysis of the kinetics of proteasome
inhibition by the standard proteasome inhibitors BTZ and MRZ, and also examined the
potential of targeting various components of the proteasome pool to augment death induction
by proteasome inhibitors.
Though both BTZ and MRZ caused strong initial proteasome inhibition, BTZ caused
more sustained proteasome inhibition, as cells treated with MRZ started to recover activity
by 8 to 16 h. This was unexpected, given the irreversible nature of MRZ. Therefore, I
performed a more thorough analysis of the reasons for this dynamic. MRZ potency was
unaffected by an inhibitor of P-glycoprotein drug efflux, and MRZ was able to bind and
inhibit proteasomes in cell lysates in a manner similar to BTZ. Preliminary experiments with
irreversible and reversible analogs of MRZ indicated there was a clear difference between the
classes, with irreversibility being important for more sustained proteasome inhibition and
effects on viability. Interestingly, BTZ behaved more similarly to the group of irreversible
inhibitors in the LN18 GBM cells.
Washout experiments demonstrated that MRZ was able to cause greater proteasome
inhibition and DNA fragmentation after short exposures, while BTZ required longer
exposure times. This may be an important factor that makes MRZ a more potent clinical
inhibitor. Therefore, my hypothesis that MRZ would cause more sustained proteasome
inhibition due to its irreversible nature was only true for pulse treatments; with continuous
treatment, BTZ was able to more fully block proteasome activity.
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In addition to targeting standard subunits, the efficacy of targeting the
immunoproteasome was also examined. The immunoproteasome-specific inhibitor ONX0914 did not strongly induce DNA fragmentation as a single agent. Also, at doses that were
specific for immunoproteasome inhibition, ONX-0914 did not potentiate death induction by
the standard inhibitors BTZ and MRZ.
The importance of PA28γ in GBM was also examined, and I determined that
combined knockdown of PA28γ and treatment with BTZ and MRZ did not lead to strong
potentiation of cell death.
Together, the work in this chapter demonstrated that BTZ and MRZ cause strong
inhibition of proteasome activity, though with different kinetics. While BTZ is stronger after
continuous treatment, MRZ may have greater effects after shorter exposures. Additional
targeting of various proteasome components with ONX-0914 or PA28γ siRNA did not
significantly augment the effects of BTZ and MRZ, indicating that these drugs alone are the
most promising method for targeting the proteasome in GBM.
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Chapter 3
Induction of caspase 9-dependent death by BTZ and MRZ and attenuation of death by thiol
reducing agents in GBM.
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Specific Aim 2: Determine the mechanism of death induction by BTZ and MRZ in
GBM.
Having determined the kinetics of proteasome inhibition by BTZ and MRZ in
Chapter 2, this chapter focuses on the mechanism of death induced by these inhibitors in
GBM cells. Previous studies have indicated that proteasome inhibitors induce caspasedependent death in other types of cancer [66-68]. I hypothesized that BTZ and MRZ would
induce caspases in GBM, and that understanding the hierarchy of caspase activation would
help in selection of biomarkers of drug efficacy and prediction of therapeutic resistance.
After examining multiple indicators of death induced by proteasome inhibitors, I examined
the dependence of this death on caspases. Using chemical inhibitors of caspases as well as
siRNA and shRNA knockdown methods, I probed the role of individual initiator caspases:
caspases 2, 8, and 9.
I also examined the role of ROS, which has been previously reported as a mechanism
of death induction by proteasome inhibitors, on mitochondrial events and cell death. To do
this, I used the reducing agents NAC and DTT, as well as direct treatment of cells with the
antioxidant GSH ethyl ester (GSHee).
This data provides insight into the mechanism of death induced by proteasome
inhibitors in GBM, which is key for providing biomarkers of drug efficacy and for helping
anticipate potential mechanisms of resistance. Also, the examination of the role of ROS in
proteasome inhibitor-induced death in GBM lends further insight into the mechanism of
death and has interesting implications for combined use of proteasome inhibitors with
antioxidants for prevention of side effects such as BTZ-induced peripheral neuropathy.
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Caspase-dependence of death induction by proteasome inhibitors in GBM.
To examine the ability of proteasome inhibitors to induce death in GBM cells, LN18,
SNB19, and U251 GBM cells were treated with increasing doses of BTZ or MRZ for 48 h,
followed by analysis of trypan blue exclusion to measure viability. Both BTZ and MRZ
decreased viability (Fig. 3.1A). The drug concentrations that caused a 50% decrease in
viability, which were determined from the dose-response curves, were in the nanomolar
range for both BTZ and MRZ (Fig. 3.1B). BTZ caused death at lower doses than MRZ, as
indicated by the significant differences between the IC50 values in all 3 lines. This was
consistent with the fact that BTZ produced longer-lasting proteasome inhibition compared to
MRZ (Fig. 2.1A-B).
Both MRZ and BTZ also increased DNA fragmentation as measured by staining with
propidium iodide followed by flow cytometry analysis of the subdiploid population. BTZ
once again caused 50% DNA fragmentation at a lower dose than MRZ (IC50: BTZ = 15 nM,
MRZ = 290 nM; Fig. 3.2). To examine the effect of proteasome inhibition, LN18 cells were
grown in soft agarose for 5 days, followed by treatment with proteasome inhibitors for 3
days. After the treatment period, colonies were analyzed by multiplying the colony number
by the colony volume to reach a value for “biomass.” Consistent with results from trypan
blue staining and DNA fragmentation analysis, BTZ also caused greater inhibition of colony
growth than MRZ (Fig. 3.3).
Previous reports in other models have suggested an important role for caspases in
proteasome inhibitor-induced death [62, 68]. To assess whether this is also the case in GBM,
I examined caspase cleavage, which is an early step that leads to activation, of the initiator
caspases 2, 8, and 9 in LN18 cells treated with MRZ or BTZ for 4, 8, 12, or 16 h.
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Figure 3.1: Reduction in cell viability after proteasome inhibitor
treatment in GBM cell lines. A) LN18, SNB19, and U251 GBM cells
treated for 48 h with proteasome inhibitors. Viability was determined by
trypan blue exclusion. B) IC50 values calculated from (A) and p-values
showing significant differences between MRZ and BTZ for each cell line.
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Figure 3.3: Reduction in colony growth by proteasome inhibitors. LN18
cells were grown in soft agarose for 5 days, followed by 3 days of treatment
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Intermediate cleavage bands, which indicate the initial processing of caspases that
often leads to activation, were visible for all 3 initiator caspases after treatment with BTZ and
MRZ (Fig. 3.4A). Notably, caspase 2 was cleaved early (4 h), particularly with MRZ
treatment, whereas caspases 8 and 9 were cleaved later (8–12 h). Activity of the executioner
caspases 3/7 was also measured using a fluorogenic substrate for these caspases, DEVD-amc.
Caspase 3/7 activity was detected 16–24 h following treatment with BTZ and MRZ (Fig.
3.4B).
To assess whether caspases were necessary for cell death, DNA fragmentation was
assessed in LN18 cells pre-treated with the pan-caspase inhibitor z-VAD-fmk. This inhibitor
blocked nearly all of the DNA fragmentation induced by BTZ and MRZ, indicating that
caspases play a crucial role in death induction by proteasome inhibitors in GBM cells (Fig.
3.5).
Early cleavage of caspase 2 by proteasome inhibitors may impede death.
Since caspase 2 was cleaved early after proteasome inhibition (4 h after MRZ
treatment), I further examined the role of caspase 2 in proteasome inhibitor-induced death.
To confirm whether the caspase 2 cleavage I observed represented caspase 2 activation
following proteasome inhibition, I employed a more direct method for assessing caspase 2
activation. I used a system in which LN18 cells were transfected with a mitochondrial marker
(dsRed mito) as well as plasmids encoding 2 halves of the Venus bimolecular fluorescence
(BiFC) protein fused to caspase 2 CARD domains. Caspase 2 recruitment to activation
platforms is required for its activation, and this brings the CARD domains attached to Venus
BiFC into induced proximity and joins together the halves of the Venus BiFC protein;
therefore, activation of caspase 2 causes Venus BiFC fluorescence. This is a novel
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technique that allows for live imaging of a definitive step in caspase activation, giving a clear
readout of caspase 2 activation signaling. Using this fluorescence microscopy-based system,
a video was recorded of LN18 cells treated with MRZ, BTZ, or another proteasome inhibitor,
carfilzomib (CFZ). The video is composed of images taken of individual cells every 5
minutes for 8 h. Representative images in Figure 3.6A show the appearance of caspase 2
BiFC fluorescence (green) against the background of the mitochondrial fluorescence (red).
The average Venus fluorescence intensity was quantified for multiple cells over the course of
8 h (Fig. 3.6B). This analysis revealed that both MRZ and BTZ induced caspase 2 BiFC,
indicating that both inhibitors induced caspase 2 activation. MRZ induced caspase 2
activation slightly earlier than BTZ, and CFZ only caused very low levels of caspase 2
activation.
To examine the importance of caspase 2 in proteasome inhibitor-induced death, 2
separate siRNA sequences were used to transiently reduce caspase 2 in LN18 cells (Fig.
3.7A). After transfection with siCASP2, cells were then treated with proteasome inhibitors.
Knockdown of caspase 2 did not significantly alter DNA fragmentation induced by either
BTZ or MRZ (Fig. 3.7B). Similarly, siCASP2 did not significantly impact the reduction in
viability caused by BTZ and MRZ (Fig. 3.7D).
In previous studies, active caspase 2 induced mitochondrial membrane permeability
and activation of caspase 9 [74, 75]. However, knockdown of caspase 2 did not reduce
cleavage of caspase 9 by Western blot in LN18 cells treated for 16 h with BTZ or MRZ (Fig.
3.7C). Together, this data indicates that transient knockdown of caspase 2 does not impact
cleavage of downstream caspase 9 or eventual cell death.
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Figure 3.6: Activation of caspase 2 by proteasome inhibitors. A) Still images from live imaging
of LN18 cells treated with 290 nM MRZ, 15 nM BTZ, or 250 nM carfilzomib (CFZ). Caspase 2
induced proximity was imaged using the VENUS BiFC-caspase 2-CARD system. Red fluorescence
is dsRed mitochondria, YFP is VENUS BiFC-caspase 2. B) Quantification of average intensity of
VENUS BiFC from (A) for LN18 cells treated with DMSO (N = 8 cells), BTZ (N = 14 cells), MRZ
(N = 13 cells), or CFZ (N=17 cells).
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It is possible that the transient nature of the siRNA knockdown was insufficient to
fully block caspase 2 activity. Therefore, I generated LN18 cells stably expressing caspase 2
shRNA (Fig. 3.8A). Similarly to the siCASP2, I found that shCASP2 did not block cleavage
of other caspases following treatment with BTZ or MRZ. In fact, there was increased
cleavage of caspase 9 (Fig. 3.8B) and increased caspase 3/7 activity (Fig. 3.8C) in shCASP2
cells treated with proteasome inhibitors. To see if these increases in caspase activation
resulted in changes in death, I measured DNA fragmentation in shCTRL and shCASP2 cells
treated for either 24 h (Fig. 3.9A) or 48 h (Fig. 3.9B) with proteasome inhibitors. At both
timepoints, there were indications that shCASP2 cells were slightly more sensitive to
proteasome inhibitors than shCTRL cells.
To confirm this, the proteasome inhibitor sensitivity of wild-type MEFs and caspase 2
deficient MEFs was examined (Fig. 3.10). There was slightly less DNA fragmentation in
caspase 2 deficient MEFs treated with select doses (50 nM MRZ and 100 nM BTZ) of the
proteasome inhibitors, but overall, caspase 2 deficiency did not have a large impact on
sensitivity to proteasome inhibitors. These results indicate that caspase 2 is not essential for
death induction following proteasome inhibition in GBM cells.
Caspase 9 functions upstream of caspase 8 to induce death after proteasome inhibition.
We next examined the initiator caspases 8 and 9, which were both activated 8–12 h
following treatment with either BTZ or MRZ (Fig. 3.4A). Previous reports have found
differences in the caspase-dependence of death induced by BTZ and MRZ, with MRZ being
more dependent on caspase 8 in leukemia, and BTZ being more equally dependent on
caspases 8 and 9 in myeloma [68, 143]. Therefore, I set out to examine the specific caspase
dependence of these agents in GBM.
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Figure 3.8: Increased caspase
activation and death in shCASP2 cells
in response to proteasome inhibitors.
A) Western blot for caspase 2 in lysates
from LN18 cells stably expressing
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Figure 3.10: Caspase 2 +/+ MEFs
and caspase 2 -/- MEFs are
similarly sensitive to proteasome
inhibitors. Caspase 2 +/+ and -/MEFs were treated for 48 h with
proteasome inhibitors (MRZ and
BTZ), followed by propidium iodide
staining for analysis of DNA
fragmentation (*p < 0.05).

LN18 cells pre-treated with specific inhibitors of either caspase 8 (z-IETD-fmk) or
caspase 9 (z-LEHD-fmk) were significantly protected from both BTZ- and MRZ-induced
DNA fragmentation (Fig. 3.11). To identify whether caspase 8 or 9 was the initiator of the
caspase cascade, I examined whether chemical inhibition of either caspase 8 or 9 blocked
activation of the other caspase following proteasome inhibition. Notably, these inhibitors
block active caspases by acting as specific substrates; therefore, these inhibitors do not
prevent initial cleavage and activation of the targeted caspase, but they do bind and inhibit
the active caspase to prevent activation of downstream caspases. Using Western blotting to
examine cleavage of caspases 8 and 9, I found that inhibition of caspase 8 did not prevent
cleavage of caspase 9. However, inhibition of caspase 9 did prevent cleavage of caspase 8
(Fig. 3.12A). Densitometry was used to determine how the specific inhibitors impacted the
ratios of cleaved to whole caspases. This analysis confirmed that treatment with the caspase 9
inhibitor did reduce the amount of cleaved caspase 8 (Fig. 3.12B), while treatment with the
caspase 8 inhibitor did not reduce caspase 9 cleavage (Fig. 3.12C). Therefore, using chemical
inhibitors, I determined that caspase 9 was the initiating caspase upstream of caspase 8
cleavage in LN18 cells.
Caspases have overlapping cleavage site specificities, so chemical inhibitors are not
specific for any one caspase family member [144]. Therefore, I confirmed the chemical
inhibitor results in cells stably expressing shRNA for caspase 8 or 9. Western blot analysis
was used to examine cleavage of caspases 8 and 9 in shCASP8 and shCASP9 cells treated for
16 h with BTZ and MRZ (Fig. 3.13A). Cleavage of caspase 8 was blocked in the shCASP9
cells, which was visible on the Western blot and was confirmed by densitometry analysis that
showed a reduction in cleaved caspase 8 in shCASP9 cells (Fig. 3.13B).
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Alternatively, caspase 9 cleavage was actually increased in shCASP8 cells treated
with BTZ and MRZ; this increase was confirmed by densitometry analysis (Fig. 3.13C).
Together, data from both chemical inhibitors and shRNA indicates that caspase 9 cleavage is
necessary for caspase 8 cleavage by proteasome inhibitors, placing caspase 9 at the top of the
apoptotic cascade induced by both BTZ and MRZ in GBM cells.
I also assessed DNA fragmentation in shCASP8 and shCASP9 cells 24 h after
proteasome inhibitor treatment and found that shCASP8 cells showed decreased sensitivity to
MRZ, but not BTZ (Fig. 3.14A). Notably, the shCASP9 cells were more resistant to both
MRZ and BTZ, indicating that caspase 9 is important for initial death induction by both BTZ
and MRZ (Fig. 3.14B). When I examined DNA fragmentation after 48 h of treatment, effects
on death were blunted; BTZ treatment caused slightly increased DNA fragmentation in
shCASP8 cells and slightly decreased DNA fragmentation in shCASP9 cells compared to
shCTRL cells (Fig. 3.15A-B). This may indicate that late compensatory mechanisms
obscured the effects of the initiator caspases, but the data at 24 h confirms that caspase 9 is
important for death induced by both BTZ and MRZ.
Role of the mitochondria in proteasome inhibitor-induced death.
Caspase 9 is activated downstream of mitochondrial membrane permeabilization,
which releases cytochrome C and enables formation of the apoptosome [72]. Since caspase 9
was found to be the initiator of caspase-dependent apoptosis, I next looked at mitochondrial
events after proteasome inhibition. LN18 cells were treated with proteasome inhibitors for 8
h, followed by brief, gentle lysis of outer membranes and pelleting of mitochondria to obtain
cytoplasmic fractions. Cytochrome C was then examined by Western blot in these cells.
Treatment with staurosporine (STS), an ATP-competitive protein kinase inhibitor known to
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induce mitochondria permeability and cytochrome C release [145], was used as a control.
Both BTZ and MRZ induced release of cytochrome C from the mitochondria into
cytoplasmic fractions (Fig. 3.16). Decreases in mitochondrial membrane potential were also
measured using tetramethylrhodamine, ethyl ester (TMRE), a dye that is retained in intact
mitochondria. Representative histograms are shown for flow cytometric analysis of TMRE
staining of LN18 cells treated for 16 h with STS or proteasome inhibitors (Fig. 3.17A). The
mean fluorescence was recorded for TMRE-stained cells treated with proteasome inhibitors
for 4 to 16 h. Mitochondrial membrane potential significantly increased 12 to 16 h following
treatment with both BTZ and MRZ (Fig. 3.17B). This data confirms the occurrence of
upstream events necessary for caspase 9 activation by proteasome inhibitors.
To further investigate the role of the mitochondria in proteasome inhibitor-induced
death, LN18 cells were generated that expressed either vector (PLRS) or the anti-apoptotic
Bcl-2 family member Bcl-XL, which blocks mitochondrial permeability by binding to BH3
domains of pro-apoptotic Bcl-2 family members (Fig. 3.18A) [146]. Cells that overexpressed
Bcl-XL were less sensitive to both MRZ- and BTZ-induced DNA fragmentation (Fig.
3.18B). I examined the functional effect of Bcl-XL overexpression on mitochondrial
permeability and subsequent cleavage of caspase 9 (Fig. 3.19). Cells overexpressing Bcl-XL
still had decreases in mitochondrial membrane potential, and caspase 9 was still cleaved after
proteasome inhibitor treatment. Bcl-XL did prevent caspase 9 cleavage in response to
staurosporine treatment, indicating that the overexpression did protect against another agent
that has been shown to cause mitochondrial permeability. The fact that Bcl-XL conferred
partial protection from DNA fragmentation but not caspase 9 cleavage after proteasome
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Figure 3.16: Proteasome inhibitors induce
release of cytochrome C into the
cytoplasm. LN18 cells treated 16 h with
100 nM MRZ or BTZ, or 8 h with 0.5 µM
STS. Cells were separated into cytoplasmic
and mitochondrial fractions, and the
cytoplasmic fractions (shown here) were
probed for cytochrome C.
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inhibitor treatment suggests that Bcl-XL overexpression has effects other than protection of
mitochondrial membrane permeability.
Caspase 9 activation and death are blocked by reducing agents.
Past studies have indicated that production of ROS is an integral part of proteasome
inhibitor-induced death in other types of cancer [47, 68, 82, 84]. To see if this was the case in
GBM, LN18 cells were treated with proteasome inhibitors, followed by measurement of
hydrogen peroxide by incubation with CM-H2DCFDA or superoxides by incubation with
hydroethidium. Levels of these species in cells were measured by flow cytometric analysis.
Both BTZ and MRZ caused only minimal increases in ROS, as is shown by representative
histograms for hydrogen peroxide (Fig. 3.20A) and superoxide (Fig. 3.20B) levels, as well as
by quantification of the mean fluorescence for these dyes in cells treated with BTZ or MRZ
for 4 to 12 h (Fig. 3.20C-D).
Despite minimal ROS increases, it is possible that any perturbation of the oxidative
state of cells could be important for proteasome inhibitor induced death. Therefore, I
continued to explore the importance of ROS by pre-treating cells with antioxidants to see if
this impacted activation of death following proteasome inhibition. NAC is commonly used as
an antioxidant due to its ability to flood cells with free cysteine, which is a key step for
production of the antioxidant glutathione (GSH) [147].
When LN18 cells were pre-treated with NAC, proteasome inhibitor-induced cleavage
of caspase 2 was reduced on Western blot (Fig. 3.21A). Inhibition of caspase 2 activation
was confirmed in LN18 cells transfected with caspase 2 Venus BiFC. The percentage of cells
that were positive for caspase 2 BiFC signal were quantified either 4 h (Fig. 3.21B) or 24 h
(Fig. 3.21C) following treatment with proteasome inhibitors. There were only minor
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increases in the percentage of caspase 2 BiFC positive cells at 4 h. However, at 24 h, pretreatment with NAC did prevent activation of caspase 2 after treatment with certain lower
doses (100 nM MRZ, 15 nM BTZ) of proteasome inhibitors. Given my previous result that
caspase 2 is not essential for death induction by proteasome inhibitors (Fig. 3.7-10), it is
unclear what effect preventing activation of caspase 2 may have in GBM cells. However, it is
clear that its activation is modulated by NAC.
Since I previously determined that caspase 9 was at the top of the hierarchy of
caspase activation by proteasome inhibitors in GBM cells (Fig. 3.12-13), I went on to
explore the effect of antioxidant treatment on caspase 9. I pre-treated cells with either NAC
or dithiothrietol (DTT). Both NAC and DTT can act as general reducing agents that modulate
cellular thiol levels [148]. Mitochondrial release of cytochrome C into cytoplasmic fractions
and cleavage of caspase 9 were attenuated in cells pre-treated with NAC or, to a slightly
lesser extent, DTT (Fig. 3.22A). Caspase 3/7 activity was also decreased in cells treated with
NAC before proteasome inhibition (Fig. 3.22B).
Since NAC and DTT blocked caspase activation, I examined whether this
corresponded to decreased induction of cell death. Cells pre-treated for 30 min with either
NAC or DTT, followed by 48 h treatment with BTZ or MRZ, were examined for DNA
fragmentation. Both NAC and DTT caused a strong reduction in DNA fragmentation induced
by BTZ and MRZ (Fig. 3.23).
Since the mechanism of NAC as an antioxidant is widely considered to be through
increased GSH, I also pre-treated cells with a cell-soluble form of glutathione (glutathione
ethyl ester, GSHee). However, GSHee did not prevent proteasome inhibitor-induced DNA
fragmentation (Fig. 3.23). To ensure that both NAC and GSHee were causing increases in
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GSH, cellular GSH levels were measured using monochlorobimane. Once
monochlorobimane enters cells, glutathione S-transferases facilitate the formation of GSHmonochlorobimane adducts, which can be measured by fluorescence [149]. Using this
method, I was able to see that both NAC and GSHee increased cellular GSH to a similar
degree (Fig. 3.24). Since both NAC and GSHee increase GSH, but only NAC protects cells
from proteasome inhibitor-induced DNA fragmentation, NAC is functioning independently
of its impact on GSH.
To further confirm this, I conducted experiments using buthionine sulfoximine
(BSO), an inhibitor of γ-glutamylcysteine synthetase, which is critical for GSH synthesis
[150]. Pre-treating LN18 cells with BSO depleted GSH levels, and also prevented NACinduced increases in GSH (Fig. 3.24). BSO treatment (GSH depletion) had minimal and
opposing effects on proteasome inhibitor-induced DNA fragmentation (increased sensitivity
to MRZ, slightly decreased sensitivity to BTZ). Most importantly, NAC still protected cells
from BTZ and MRZ induced death, even when pre-treatment with BSO prevented NAC from
increasing GSH (Fig. 3.24). This confirms that NAC protects cells from proteasome
inhibitor-induced death in a manner independent of GSH.
There have been some reports of direct inactivation and prevention of antitumor
efficacy of BTZ by certain antioxidants, including Vitamin C and green tea components such
as (-)-epigallocatechin gallate (EGCG) [85, 151, 152]. To see whether the effects of NAC
and DTT were due to direct prevention of proteasome binding and inhibition by BTZ and
MRZ, proteasome activity was measured in LN18 cells pre-treated with NAC and DTT,
followed by treatment with BTZ and MRZ.
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Figure 3.25: NAC and DTT do not
suppress the ability of proteasome
inhibitors to reduce CT-L proteasome
activity. LN18 cells pre-treated 30 min
with NAC or DTT were then treated 4 h
with proteasome inhibitors. CT-L
proteasome activity was assessed using
the fluorogenic substrate suc-LLVY-amc
(*p < 0.05).

Neither NAC nor DTT affected the ability of BTZ or MRZ to inhibit proteasome activity,
indicating that they are not directly acting on these agents (Fig. 3.25). There was 1 dose of
MRZ that was slightly attenuated by NAC. However, higher doses were not affected, and
strong protection from death was observed under conditions where proteasome inhibition
capacity was not altered (Fig. 3.23).
Together, these results demonstrate that the reducing agents NAC and DTT protect
cells from proteasome inhibitor-induced death in a manner independent of GSH or direct
effects on the ability of these drugs to inhibit proteasome activity.
BTZ and MRZ do not deplete cellular amino acid levels.
A report by Suraweera et al. [153] suggested an alternative hypothesis for the
mechanism of proteasome inhibitor-induced death. They found that MEFs treated with the
proteasome inhibitors MG-132 or BTZ had a quick decline in free amino acid levels,
particularly of the amino acids cysteine and asparagine. This depletion induced cellular
starvation signaling, increasing GCN2 signaling and autophagy. Notably, supplementing
cells with the amino acid cysteine greatly protected against cell death, and supplementing
with asparagine also slightly protected cells from proteasome inhibitor-induced death.
Since NAC introduces large amounts of cysteine into cells, I wanted to explore
whether the amino acid starvation theory of proteasome inhibitor efficacy could apply to
GBM cells. First, I pre-treated cells with NAC as well as asparagine to see if another amino
acid would have an effect. Asparagine did lend some protection, particularly in cells treated
with both asparagine and cysteine, followed by 100 nM BTZ (Fig. 3.26A). Asparagine was
not as protective as NAC, which was consistent with the published results in MEFs [153].
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When I supplemented cells with cysteine (instead of NAC) as well as asparagine, similar
trends were observed; though asparagine had little impact on its own, it slightly augmented
the protection conferred by cysteine (Fig. 3.26B).
The selection of cysteine and asparagine was based on the fact that these amino acids
were strongly depleted in MEFs treated with proteasome inhibitors [153]. However, these
same amino acids may not be the key amino acids depleted by proteasome inhibition in GBM
cells. Therefore, I wanted to determine the amino acid profile of cells following treatment
with BTZ and MRZ to see if particular amino acids were depleted. To do this, I collaborated
with the MD Anderson Cancer Center Proteomics Core. I used a mass spectrometry-based
approach for amino acid measurement [154]. Using this method, I was able to determine that
there were not widespread decreases in amino acids following proteasome inhibition in LN18
GBM cells (Fig. 3.27). In fact, many amino acids, including cysteine and asparagine, actually
increased slightly after proteasome inhibitor treatment. Since most amino acids were
increased after proteasome inhibition, not decreased, it is unlikely that amino acid starvation
is a main method triggering death in GBM cells following proteasome inhibition. Likewise,
cysteine supplementation by NAC is most likely not its mechanism of protection.
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Figure 3.27: Amino acid and metabolite levels after treatment with proteasome inhibitors.
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85

Summary
The work in this chapter provides a detailed examination of the kinetics and
mechanism of death induction by initiator caspases in GBM cells treated with the proteasome
inhibitors BTZ and MRZ. Proteasome inhibitor-induced death was apparent by multiple
measures; loss of viability, induction of DNA fragmentation, and inhibition of colony growth.
GBM cells were sensitive to BTZ at lower doses than MRZ, which corresponds to the more
sustained proteasome inhibition after BTZ treatment that was observed in Chapter 2.
However, both inhibitors induced death at reasonably low doses in the nanomolar range.
As I hypothesized, both BTZ and MRZ did activate caspases in GBM cells. A key
part of this chapter is the examination of the time course of activation as well as the relative
dependence of BTZ and MRZ on each initiator caspase. While caspase 2 was activated
quickly after treatment with BTZ and MRZ (4 h), knockdown experiments revealed that it is
not essential for death induction by these inhibitors. Subsequent experiments determined that
caspase 9 is the initiating caspase for both BTZ- and MRZ-induced death in GBM cells.
This chapter also identified that the reducing agents NAC and DTT blocked
mitochondrial release of cytochrome C, caspase 9 activation, and cell death induced by
proteasome inhibitors. This protection was independent of effects on GSH or the ability of
BTZ and MRZ to inhibit the proteasome. I also demonstrated that amino acids are not
depleted following BTZ and MRZ treatment in GBM cells, indicating that NAC is likely not
acting by rescuing cells from amino acid starvation following proteasome inhibition. Given
the similarities between NAC and DTT, which both modulate cellular thiol levels, it is likely
that these agents are acting as more general reducing agents. These experiments provide
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supporting evidence that a stimulus that prevents caspase activation also prevents final death
induction, drawing an additional indirect correlation between these events.
As I hypothesized, delineation of the pathway of caspase activation does give clues to
potential biomarkers of drug efficacy and resistance. Since I determined that caspase 9 is the
apical caspase in apoptosis induced by BTZ and MRZ in GBM, efficacy could be monitored
by examining events such as mitochondrial membrane permeability and cleavage of caspase
substrates. Additionally, based on the role of caspase 9 defined here, future studies of
proteasome inhibitor resistance in GBM could focus on the role of antagonists of this
pathway, such as anti-apoptotic Bcl-2 family members and IAP proteins.
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Chapter 4
BTZ and MRZ modulation of proteasome substrates in orthtopic brain tumors, and in vitro
and in vivo synergy between proteasome inhibitors and HDACi in GBM.
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Specific Aim 3: Evaluate the ability of BTZ and MRZ to inhibit proteasomes and
induce death in combination with HDACi in an orthotopic GBM model.
This chapter examines questions relevant to establishing the clinical potential of the
proteasome inhibitors BTZ and MRZ. Past studies have not definitively answered questions
about the ability of BTZ and MRZ to exert functional effects on proteasomes in brain tumors
in relevant models [97, 99]. Additionally, combination strategies that potentiate the
mechanism of death induced by BTZ and MRZ are needed to enhance their clinical potential.
Therefore, I hypothesized that examination of the molecular effects of BTZ and MRZ in an
orthotopic brain tumor model would establish a framework for their clinical use.
First, an orthotopic intracranial GBM xenograft mouse model was used to examine
the ability of BTZ and MRZ to cause accumulation of proteasome substrates in brain tumors.
Next, combination therapy strategies that could enhance the efficacy of proteasome inhibitors
were examined. Based on my previous data showing that proteasome inhibitors induce
caspase-dependent death, I considered combinations that could potentiate the effectiveness of
caspase activation. Since IAP family members bind and inhibit caspases, it is possible that
they are capable of attenuating the caspase cascade in proteasome inhibitor-treated cells.
Therefore, I examined combinations of proteasome inhibitors with the therapeutic agents
birinapant and LCL-161, which are mimetics of Smac, a cellular inhibitor of IAPs.
Combinations of proteasome inhibitors and HDACi were also examined for
synergistic effects on death induction in vitro. Multiple HDACi were tested: the pan-HDACi
vorinostat and panobinostat, and the class I HDACi entinostat. Potential interactions between
the proteasome system and HDACs were examined by looking at the effects of proteasome
inhibitors on acetylation, and the effect of HDACi on proteasome catalytic subunit mRNA.
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Potentiation of caspase 9 cleavage by the combination of HDACi and proteasome inhibitors
was also examined.
Finally, the potential of the HDACi and proteasome inhibitor combination was tested
in an orthotopic mouse model. Brain tumors from mice treated with combinations of
vorinostat plus BTZ or MRZ were examined for cleaved caspase 3 and cleavage of lamin A,
which is a caspase substrate. Overall, the work in this chapter provides information about the
ability of BTZ and MRZ to reach brain tumors and exert effects on proteasome function as
well as induction of death in combination with HDACi.
BTZ and MRZ cause accumulation of proteasome substrates in orthotopic brain
tumors.
To establish whether BTZ and MRZ are viable drug candidates for GBM, it is
important to first examine their ability to reach brain tumors at quantities high enough to
exert functional effects on the proteasome. To address this question, I used an orthotopic
model of GBM. A total of 500,000 U87 GBM cells were implanted in athymic nude mice
through a guidescrew inserted in the cranium. For the first experiment, tumors were allowed
to develop for 7 days based on a report by Lal et al. showing visible tumor formation at that
time [155]. After this time, the mice were injected intraperitoneally (IP) with a single dose of
BTZ or MRZ that was based on established maximum tolerated doses for these agents (1.0
mg/kg for BTZ and 0.15 mg/kg for MRZ). Twenty-four hours after treatment, mice were
sacrificed, and the tumor-bearing portion of the brain was isolated.
The brain tumor section was then homogenized, and lysate was examined for p27, a
cell cycle inhibitor that is also a proteasome substrate. I previously showed that p27
accumulated in LN18 GBM cells following proteasome inhibition with either BTZ or MRZ
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(Fig. 2.3). Levels of p27 were significantly elevated in the tumors of mice treated with MRZ,
but not those treated with BTZ (Fig. 4.1A). Levels of p27 were quantified using densitometry
for multiple mice (Fig. 4.1B).
As a second measure of proteasome inhibition, I examined mice treated for a more
extended period. In this case, mice implanted with U87 tumor cells were allowed to develop
tumors for 14 days. Mice were then treated for 2 weeks with twice weekly IP injections with
BTZ or MRZ. Twenty-four hours following the last treatment, mice were sacrificed and the
brains were preserved in formalin for eventual paraffin embedding and
immunohistochemistry (IHC) analysis. A hematoxylin & eosin-stained brain from a mouse in
the control group is shown in Figure 4.2A.
Sections from these mice were stained for p21, another cell cycle inhibitor that is a
proteasome substrate. Brain tumors from mice treated with either BTZ or MRZ had increases
in p21 staining as quantified by the average number of p21-positive cells per 40X field (Fig.
4.2B). Representative IHC images also show increases in p21 staining in brain tumors (Fig.
4.2C). Therefore, both BTZ and MRZ have the ability to exert functional effects on
proteasome substrates in an orthotopic brain tumor model, with MRZ exerting slightly
stronger effects, particularly on p27.
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Figure 4.1: Accumulation of p27 in brain tumors of mice
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for 7 days were treated with 1 IP injection of proteasome
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Chemical inhibitors of IAPs potentiate proteasome inhibitor-induced death, but siRNA
against IAPs does not.
An interesting trend emerged when I examined activation of initiator caspases 2, 8,
and 9 in LN18 cells treated with equipotent doses of proteasome inhibitors. Though the doses
used resulted in equal amounts of DNA fragmentation, MRZ induced more cleavage of all 3
initiator caspases compared to BTZ (Fig. 4.3A). There was also more caspase 3/7 activity in
GBM cells treated with equipotent MRZ versus BTZ (Fig. 4.3B). I hypothesized that this
may be due to a difference in IAP family members, which bind and inhibit caspases.
Specifically, XIAP, cIAP-1, and cIAP-2 can bind to caspases 9, 3, and 7 and act as ubiquitin
ligases to target caspases for degradation [114]. Based on my previous data, this indicates
that IAPs could inhibit the function of both the apical initiating caspase (caspase 9) as well as
executioner caspases following proteasome inhibition in GBM. It is possible that MRZ in
particular increased levels of an IAP, preventing death even though caspases were being
activated. If this is the case, then targeting of IAPs could potentiate death induction by
proteasome inhibitors.
Western blot analysis of XIAP protein levels showed that neither BTZ nor MRZ
increased levels of XIAP (Fig. 4.4). However, basal XIAP expression was detectable in
GBM cells, suggesting that it may be able to suppress apoptosis. I tested this possibility using
the Smac mimetics birinapant and LCL-161. Though these agents did not induce DNA
fragmentation on their own, they did potentiate the DNA fragmentation caused by both BTZ
and MRZ (Fig. 4.5A). Though other reports have indicated that Smac mimetics target IAPs
for degradation, decreasing their protein levels [156], I did not see any changes in protein
levels of either XIAP or cIAP-1 after treatment with birinapant or LCL-161 (Fig. 4.5B).
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BTZ and MRZ. A) LN18 cells were treated with equipotent doses (IC50
based on DNA fragmentation) of BTZ or MRZ, and cleavage of initiator
caspases was examined. B) Caspase 3/7 activity in LN18 cells treated 16 h
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of proteasome inhibitors (*p<0.05, NS=not significant).
95

100	
  nM	
  inhibitors	
  

IC50	
  inhibitors	
  

XIAP	
  

acDn	
  
16	
  h	
  

24	
  h	
  

16	
  h	
  

24	
  h	
  

Figure 4.4: Effect of proteasome inhibitor treatment on XIAP levels. LN18 cells
were treated for 16 or 24 h with 100 nM or IC50 doses (290 nM MRZ, 15 nM BTZ) of
proteasome inhibitors. Cell lysates were probed for XIAP.

96

A

Control
10 µM Birinapant
10 µM LCL-161

100

% Subdiploid

80

*

*

*

*

NS

*

*

*

60
40
20

B

BT
nM
0
10

nM
15

μM	
  birinapant	
  

Z

Z
BT

Z
R
M
nM
0
29

nM
10

0

D

M

M

R

Z

SO

0

μM	
  LCL-‐161	
  

XIAP	
  
cIAP-‐1	
  
acDn	
  
Figure 4.5: Death induction by combinations of proteasome inhibitors and
IAP inhibitors. A) LN18 cells were pre-treated 24 h with the IAP inhibitors
birinapant and LCL-161, followed by 48 h treatment with BTZ or MRZ and
assessment of DNA fragmentation. B) LN18 cells treated 24 h with birinapant or
LCL-161 were probed for levels of XIAP and cIAP-1.

97

Though these proteins were not degraded, the Smac mimetics still may have been disrupting
IAP-caspase binding or IAP ligase activity.
To test more specifically whether increases in death with proteasome inhibitors was
due to specific IAP targeting or off-target effects of birinapant and LCL-161, I transfected
cells with siRNA against cIAP-1, XIAP, or the combination of cIAP-1 plus XIAP, and
examined whether this sensitized cells to proteasome inhibitors. Though siRNA achieved
knockdown of cIAP-1 and XIAP (Fig. 4.6A), cells transfected with the siRNA, either alone
or in combination, were not more sensitive to proteasome inhibitors (Fig. 4.6B). Therefore,
the sensitizing effect of the chemical Smac mimetics may be due to off-target effects in these
cells. Depleting IAPs does not seem to potentiate the activity of proteasome inhibitors,
possibly due to sufficient release of Smac from mitochondria, or because other IAPs besides
cIAP-1 and XIAP are important in these cells. The synergy observed with birinapant and
LCL-161 may be due to alternative targets.
HDACi potentiate the apoptotic mechanism of BTZ and MRZ in vitro.
Studies in other cancer types such as leukemia have found that combining proteasome
inhibitors and HDACi induces synergistic cell death [139, 157]. Therefore, I investigated the
potential of this combination in GBM. I focused on combinations of BTZ and MRZ with 3
different HDACi: the pan-HDACi vorinostat and panobinostat and the class I HDACi
entinostat. LN18 cells treated with combinations of either BTZ or MRZ and vorinostat
showed strong increases in DNA fragmentation (Fig. 4.7). Similar trends were seen when
BTZ and MRZ were combined with panobinostat (Fig. 4.8).
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Figure 4.6: Death induction by proteasome
inhibitors after knockdown of IAPs. A)
LN18 cells transfected with siXIAP,
sicIAP-1, or the combination of both siRNAs
(siC + X). B) LN18 cells transfected with
siRNA were treated for 48 h with proteasome
inhibitors, followed by analysis of DNA
fragmentation.
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Figure 4.7: Increased death with proteasome inhibitors and vorinostat. LN18
cells were treated 48 h with combinations of proteasome inhibitors (MRZ and BTZ)
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Figure 4.8: Increased death with proteasome inhibitors and
panobinostat. LN18 cells were treated 48 h with combinations of
proteasome inhibitors (MRZ and BTZ) with panobinostat (*p < 0.05
compared to either single agent alone).
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The synergistic potential of these combinations was evaluated using CalcuSyn
software. This method uses the Chou and Talalay method for evaluating synergy [158].
Values <1 indicate synergistic effects, values = 1 indicate additive effects, and values >1
indicate antagonistic effects. According to this method, synergy occurred in cells treated with
multiple doses of BTZ or MRZ with vorinostat or panobinostat. In particular, the most
synergistic combinations were 10 nM BTZ or 100 nM MRZ with 5 µM vorinostat or 250 nM
panobinostat (Table 4.1).
Though the class I HDACi entinostat was also examined, it did not exert very strong
effects on DNA fragmentation when combined with proteasome inhibitors (Fig. 4.9).
Therefore, only the pan-HDACi were examined in future experiments.
Vorinostat interacts with the proteasome pathway by reducing PSMB5 mRNA.
To better understand interactions between proteasome inhibitors and HDACi, I
examined potential areas where the drug mechanisms could overlap. First, I examined
whether proteasome inhibitors could alter histone acetylation in GBM cells, which has been
previously reported for MRZ in leukemia [139]. Acid extracted histones were examined by
Western blot. Though vorinostat caused a strong accumulation of acetylated histone H3,
MRZ and BTZ did not impact these levels, either alone or in combination with vorinostat
(Fig. 4.10A). This was confirmed by densitometry analysis (Fig. 4.10B).
Next, I examined whether the HDACi vorinostat impacted levels of proteasome
catalytic subunit mRNA, which has also been previously observed in leukemia [139].
Vorinostat significantly reduced levels of PSMB5 (β5 catalytic subunit) mRNA in LN18
cells, both alone and in combination with BTZ and MRZ (Fig. 4.11).
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Prot.
Inhib.

CI:
2.5 µM
VORI

CI:
5 µM
VORI

CI:
100 nM
pano

CI:
250 nM
pano

25 nM
MRZ

0.226

0.209

0.279

0.203

100 nM
MRZ

0.117

0.075

0.304

0.102

250 nM
MRZ

0.144

0.126

0.448

0.168

10 nM
BTZ

0.217

0.100

0.376

0.086

25 nM
BTZ

0.192

0.161

0.248

0.124

100 nM
BTZ

0.766

0.527

0.497

0.396

Table 4.1: Combination index (CI) values for
synergy of proteasome inhibitors plus
HDACi. CalcuSyn software was used to
determine CI values for combinations of MRZ
and BTZ with vorinostat and panobinostat.
Values <1 are synergistic, values = 1 are
additive, and values >1 are antagonistic.
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Figure 4.9: Death induction by proteasome inhibitors and entinostat.
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Figure 4.11: Vorinostat suppresses
transcription of the proteasome
subunit PSMB5. Levels of PSMB5
mRNA were assessed in LN18 cells
treated for 8 h with proteasome
inhibitors (MRZ and BTZ) and
vorinostat.

While proteasome inhibitors caused trends toward slightly increased PSMB5 mRNA, likely
as a “bounce back” response to inhibition, this was ameliorated in cells that were also treated
with vorinostat.
To examine whether the decrease in PSMB5 mRNA had functional consequences, I
examined proteasome activity in LN18 cells treated with either vorinostat or panobinostat in
combination with proteasome inhibitors. Both vorinostat (Fig. 4.12A) and panobinostat (Fig.
4.12B) slightly decreased the CT-L proteasome activity that is associated with the β5
proteasome subunit by around 20%. Both vorinostat and panobinostat also significantly
augmented proteasome inhibition in cells treated with either BTZ or MRZ for 24 h.
Though these differences were significant, they were difficult to discern due to the
strong suppression of proteasome activity that already occurs with single agent BTZ and
MRZ treatment. Therefore, I examined whether vorinostat augmented proteasome inhibition
in cells treated with low doses of BTZ and MRZ. At the doses used (10 nM MRZ, 1 nM
BTZ, and 5 µM vorinostat), all 3 therapeutic agents reduced proteasome activity by roughly
20% to 30% as single agents (Fig. 4.13). Proteasome activity was further reduced, to roughly
50% to 60%, in cells treated with the combinations of low dose BTZ and MRZ with
vorinostat. Therefore, HDACi such as vorinostat are able to augment proteasome inhibition
caused by BTZ and MRZ, potentially increasing their therapeutic efficacy.
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Figure 4.12: Vorinostat and panobinostat suppress CT-L
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proteasome inhibitors. A-B) LN18 cells treated for 6 or 24 h
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Vorinostat augments caspase cleavage in combination with proteasome inhibitors in
vitro and in vivo.
A report in GBM cell lines found that the combination of BTZ and vorinostat induced
a strong reduction in mitochondrial membrane potential [96]. Together with my results that
the intrinsic apoptosis pathway (involving mitochondria permeability, cytochrome C release,
and activation of caspase 9) activates apoptosis after proteasome inhibition in GBM, it seems
possible that the combination of proteasome inhibitors with vorinostat causes augmented
activation of caspase 9. Indeed, when I examined caspase 9 in LN18 cells treated with the
most highly synergistic combinations of BTZ or MRZ with vorinostat, I found strong
enhancement of caspase 9 cleavage in the combination-treated cells (Fig. 4.14). Potentiation
of this mechanism by the combination indicates that markers of caspase activation, such as
cleavage of executioner caspases and their substrates, might act as markers of death induction
in brain tumors in vivo.
To examine this possibility, I once again utilized an orthotopic xenograft model, as
described at the beginning of this chapter. For these experiments, tumors were allowed to
develop for 14 days. Following this time, mice were treated for 2 weeks with a schedule of
twice weekly proteasome inhibitors (1.0 mg/kg BTZ or 0.15 mg/kg MRZ) with 5 times per
week vorinostat (50 mg/kg), all injected IP. Mice were treated both with single agents, or
with combinations of BTZ or MRZ with vorinostat. The schedule of treatment is shown in
Figure 4.15. Mice were sacrificed 24 h following the final proteasome inhibitor treatment.
Brains were preserved in formalin for later paraffin embedding and IHC analysis.
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Figure 4.14: Synergistic induction of caspase 9 cleavage by
combinations of vorinostat and proteasome inhibitors.
Caspase 9 cleavage in LN18 cells treated for 16 h with 5 µM
vorinostat with 100 nM MRZ or 10 nM BTZ for 16 h.
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Figure 4.15: Treatment schedule for mice with orthotopic brain tumors
treated with proteasome inhibitors and vorinostat. Mice were implanted with
500,000 U87 cells through intracranial guidescrews, and tumors were allowed to
develop for 2 weeks. Mice were then treated for 2 weeks with vorinostat (5 days/
week, 50 mg/kg) or twice weekly proteasome inhibitors (0.15 mg/kg MRZ or
1.0 mg/kg BTZ) injected IP. Mice were sacrificed 24 h following the last
proteasome inhibitor treatment.
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First, brain tumors were examined by IHC for cleaved caspase 3. Cleaved caspase 3
staining was faint, and only 2 brain tumors-both in the group that received MRZ plus
vorinostat-showed any positivity for cleaved caspase 3. This is clear in representative images
(Fig. 4.16A), as well as in quantification of the average number of positive cells per 40X
field for individual mice (Fig. 4.16B). Though there were only a few positive cells, it is
notable that both samples that had minor signs of positivity were in the same group (MRZ
plus vorinostat).
Next, levels of cleaved lamin A were examined in brain tumors from these mice.
Lamin A is a substrate of executioner caspases [159]. There was a marked lack of single
agent effects on lamin A cleavage. However, there were signs of lamin A cleavage in tumors
from both the BTZ plus vorinostat and MRZ plus vorinostat groups (Fig. 4.17A). The
increases in lamin A cleavage in the combination treatment groups were significant (Fig.
4.17B). There was a slight trend towards increased cleavage of lamin A in the MRZ plus
vorinostat treated brain tumors compared to the BTZ plus vorinostat treated brain tumors.
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Figure 4.16: Cleaved caspase 3 in brain tumors of mice treated with vorinostat
plus proteasome inhibitors. A) Representative images from IHC of cleaved caspase
3 in the brain tumors of mice treated for 2 weeks with combinations of vorinostat with
BTZ or MRZ (40X). B) Quantification of the average number of positively stained
cells per 40X field.
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Figure 4.17: Lamin A cleavage in brain tumors of mice treated with vorinostat plus
proteasome inhibitors. A) Representative images from IHC of cleaved lamin A in the
brain tumors of mice treated for 2 weeks with combinations of vorinostat with BTZ or
MRZ (40X). B) Average number of cells per 40X field positive for cleaved lamin A in
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Summary
In this chapter, I examined questions of key clinical importance for proteasome
inhibitors in GBM: the ability of the drugs to inhibit the proteasome in orthotopic brain
tumors, and the combination effect of proteasome inhibitors with HDACi. Two separate
proteasome substrates were examined, p21 and p27, in brain tumors of mice treated either
with a single injection of proteasome inhibitors (p27) or with twice-weekly treatment for 2
weeks (p21). Together, these results indicate that BTZ and MRZ do exert functional effects
on proteasome substrates. Notably, MRZ seems to exert slightly stronger effects, particularly
on p27, which was not elevated by BTZ treatment.
Combinations of proteasome inhibitors and HDACi revealed strong combination
effects between both BTZ and MRZ and 2 pan-HDACi, vorinostat and panobinostat.
Notably, a class I HDACi did not exert strong effects in combination with BTZ and MRZ.
Examination of potential areas of crosstalk between the mechanisms of these drugs revealed
that vorinostat reduces mRNA of the proteasome catalytic subunit PSMB5. This change in
mRNA was indicative of functional effects, as both vorinostat and panobinostat decreased
CT-L proteasome activity, both alone and in combination with proteasome inhibitors.
I also determined that the combination of proteasome inhibitors with vorinostat
augmented caspase 9 cleavage, which was shown to be important for proteasome inhibitorinduced death in Chapter 3. Following up on this result, I examined markers of caspase
activation in orthotopic brain tumors from mice treated with BTZ, MRZ, and vorinostat for 2
weeks. This experiment revealed minor increases in cleaved caspase 3 in brain tumors of
mice only in the MRZ plus vorinostat group. Additional examination of the caspase substrate
lamin A revealed that though there was a lack of single agent effects, increases in cleaved

113

lamin A were noted in mice treated either with MRZ plus vorinostat or BTZ plus vorinostat,
with a slight trend toward greater lamin A cleavage in some of the brain tumors treated with
MRZ plus vorinostat.
The results of this chapter indicate that BTZ and MRZ exert functional effects on
proteasome substrates and induce activation of caspases and cleavage of the caspase substrate
lamin A in orthotopic brain tumors. Trends such as increased p27 accumulation in brain
tumors and increased lamin A cleavage in combination with vorinostat indicate that MRZ
may have slightly more potent properties than BTZ in vivo. As I hypothesized, the work in
this chapter provided insight into the clinical utility of BTZ and MRZ by demonstrating their
ability to affect proteasome substrates as single agents and to induce death in combination
with HDACi.
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Chapter 5
Discussion and Future Directions
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The goal of this work was to characterize the proteasome inhibitory and death
inducing properties of the proteasome inhibitors BTZ and MRZ in order to establish factors
that contribute to their efficacy and their potential as therapeutic agents in GBM. This study
also sought to provide in vivo evidence of the clinical feasibility of proteasome inhibition
therapy in GBM by examining brain tumor permeance and combination therapy strategies to
enhance the efficacy of BTZ and MRZ.
Chapter 2 Discussion
Targeting standard proteasome subunits with BTZ and MRZ
The first goal of this study was to investigate the kinetics of proteasome inhibition by
BTZ and MRZ. Past studies have indicated that MRZ causes longer-lasting proteasome
inhibition in other cancer types such as leukemia, and this property is thought to be why
MRZ induces greater cell death than BTZ in some model systems [160]. The potency of
irreversible inhibitors was further established by studies of MRZ analogs. Different MRZ
analogs were developed that were either irreversible due to the presence of a leaving group
(LG analogs) in the chemical structure, or reversible due to the lack of a leaving group (nonLG analogs) [60]. The irreversible LG analogs were found to induce more sustained
proteasome inhibition and greater death than the non-LG analogs in myeloma and leukemia
[60, 61, 161]. Therefore, the question of whether proteasome inhibitors cause sustained
inhibition of proteasome activity is important for establishing their potential therapeutic
efficacy.
In a panel of GBM cell lines, I found that BTZ actually caused more sustained
inhibition of the chymotryptic-like proteasome activity than MRZ (Fig. 2.1). This was
unexpected, as it was the opposite of what was seen in the previously mentioned studies in
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hematologic malignancies. BTZ also exerted stronger effects on the caspase-like and trypsinlike activities compared to MRZ (Fig. 2.2), which is counter to past studies that have
indicated that MRZ is a stronger inhibitor of trypsin-like proteasome activity [62].
To determine possible reasons why BTZ was causing more sustained inhibition of
proteasome activity, I examined 2 possibilities: efflux of MRZ through P-glycoprotein and
differential proteasome binding ability in GBM cells. When I used verapamil to inhibit Pglycoprotein, I found that this did not enhance the activity of either BTZ or MRZ, indicating
that it is not a major mechanism of efflux for either agent (Fig. 2.5). To examine binding to
the proteasome, I examined inhibition of proteasomes by these agents in cell lysates (Fig.
2.6). Interestingly, under these conditions, both BTZ and MRZ had similar effects on the
chymotryptic-like proteasome activity at both early (1 h) and late (24 h) timepoints. Since
BTZ and MRZ demonstrate similar inhibitory abilities in lysed cells, it is likely that some
factor in the cellular milieu is attenuating MRZ, such as a compensatory increase in
proteasome subunits, inactivating modifications such as oxidation, or drug metabolism.
A study of MRZ in mice characterized proteasome activity using fluorogenic
substrates in a wide variety of tissues from 10 min to 24 h following intravenous injection
with 0.15 mg/kg MRZ [99]. In this study, MRZ initially inhibited proteasome activity in
several normal tissues including lung, liver, and kidney; however, proteasome activity in
these cells recovered within 24 h. More sustained inhibition was only observed in the blood
and in plasmacytoma tumors. This suggests that normal cells have a mechanism for
recovering proteasome activity, even after treatment with an irreversible inhibitor. It is
possible that GBM cells have a similar mechanism. One possible way this could occur is
through increased production of new proteasome subunits. My data suggests that levels of the
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catalytic subunit β5 remain steady after proteasome inhibitor treatment (Fig. 2.4) Recovery of
proteasome activity could also occur through increased proteasome assembly, which can be
facilitated by factors such as proteasome maturation protein (POMP), which facilitates
formation of proteasome core particles [162]. Future experiments analyzing proteasome
assembly, such as by analysis of POMP or by examination of assembled proteasome levels
using native gel electrophoresis would be informative about whether MRZ-treated LN18
cells recover proteasome activity through changes in assembled proteasomes.
Another explanation is that MRZ could be metabolized or subject to inactivating
modifications in GBM cells. Past studies of BTZ have revealed that Vitamin C can directly
bind to BTZ and inhibit its function [85]; similar mechanisms could exist for MRZ.
Experiments that determine whether MRZ is sensitive to oxidation or other inactivating
modifications would be informative on this issue. Pharmacodynamic studies of MRZ have
indicated that it is relatively stable in vivo, indicating that drug inactivation does not seem to
be a major issue [99]. In addition, the data presented in this study indicates that MRZ affects
proteasome substrates in brain tumors 24 h after injection of mice (Fig. 4.1-2); therefore, the
effects of MRZ are reasonably sustained in vivo.
As an additional measure of proteasome inhibition, I examined proteasome activity
and DNA fragmentation after shorter pulse treatments (2–24 h) with BTZ and MRZ (Fig.
2.7). This is an important indicator of clinical potential, as it likely mirrors in vivo conditions
better than continuous treatment. Past experiments with radiolabeled MRZ indicated that the
levels of MRZ in mouse blood and kidneys spiked within 30 min of treatment before quickly
diminishing [163]. Under these conditions, it is important that the inhibitors can cause strong
proteasome inhibition with only a short exposure time.
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In GBM cells, short (2 h) and long (24 h) exposure to MRZ had very similar effects in
terms of reduction in proteasome activity and induction of cell death. However, BTZ
required longer exposure times to cause significant effects, and effects on proteasome
activity and death induction were amplified as exposure time increased. Therefore, while
BTZ can cause stronger effects overall with continuous exposure, MRZ is more potent after
brief exposure. This could have important implications for clinical efficacy.
Lastly, to further explore the kinetics of MRZ in GBM, I examined the effects of a
variety of irreversible (LG) versus reversible (non-LG) analogs of MRZ (Fig. 2.8). Since
MRZ-treated GBM cells recovered proteasome activity, I was curious to see if there was still
a clearly defined difference between MRZ and its reversible analogs. I hypothesized that the
irreversible nature of MRZ may be compromised in GBM, leading to a lack of distinction
between these analogs. However, there were still clear differences between the two classes of
agents; irreversible analogs caused longer lasting proteasome inhibition and greater decreases
in viability compared to reversible analogs. Therefore, the presence of the LG still enhances
the potency of MRZ. Interestingly, BTZ behaved more like one of the irreversible analogs in
terms of degree of proteasome inhibition and decreases in viability at a dose that was 1/10 the
dose of the MRZ analogs (10 nM BTZ versus 100 nM analogs). This indicates that BTZ is
simply more potent in these cells. Future experiments focused on the effect of the proteasome
inhibitors on various proteasome subunits and assembly as well as examination of drug
metabolism in these cells could help explain the enhanced potency of BTZ compared to MRZ
in vitro.
Though BTZ treatment was more advantageous in vitro, my data in an orthotopic
brain tumor model indicated that MRZ more potently caused accumulation of proteasome
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substrates, and also caused slightly stronger effects on death activation in combination with
vorinostat. Therefore, MRZ may have increased clinical utility despite differences in the
dynamics of proteasome inhibition in vitro.
Targeting the immunoproteasome in GBM
Immunoproteasome subunits were found to be overexpressed in a subset of GBM
tumors by immunohistochemistry [40], and my analysis of the REMBRANDT database
showed that they are also more highly expressed in GBM tumors versus normal brain (Fig.
2.9B). Further analysis of the REMBRANDT database showed that lower LMP7 (β5i)
expression was associated with better overall survival of glioma patients (Fig. 2.10).
Therefore, I hypothesized that targeting the immunoproteasome may be effective for GBM
therapy. However, inhibiting the immunoproteasome with ONX-0914, a specific inhibitor of
β5i, did not cause much cell death (Fig. 15). This is likely because the immunoproteasome
constitutes only a fraction of the proteasome pool in GBM cells. Therefore, dual targeting of
the standard and immunoproteasome may be a more effective therapeutic strategy.
For combination with standard proteasome inhibitors, I wanted to ensure the doses of
ONX-0914 I was using were specifically targeting only the immunoproteasome. At high
doses, ONX-0914 loses specificity and also inhibits β5. To ensure that the doses I was using
were specifically inhibiting only the immunoproteasome, I used the ELISA-based ProCISE
assay, which can measure binding of agents to each standard and immunoproteasome subunit
(Fig. 2.12). Having established which doses were specific, I tested combinations of ONX0914 with BTZ and MRZ. The combinations did not show increases in DNA fragmentation,
indicating that addition of a specific immunoproteasome inhibitor did not enhance the
potency of either BTZ or MRZ.
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One main reason for this may be the fact that BTZ and MRZ can already affect
immunoproteasome subunits on their own. Though the main target of these drugs is the
standard proteasome, the active sites of the proteasome are so similar that the drugs often
react with other subunits. It can be difficult to determine whether immunoproteasome activity
is inhibited, as the fluorogenic substrates commonly used to measure proteasome activity do
not distinguish between proteasome and immunoproteasome activity. Berkers et al. used a
probe for proteasome active sites to demonstrate that BTZ can bind to multiple proteasome
catalytic subunits, including β1i and β5i [43]. To really determine whether targeting the
immunoproteasome enhances ubiquitin-proteasome system targeting in GBM, it would be
necessary to use an agent that specifically targets only the standard proteasome; its lack of
immunoproteasome-targeting would need to be confirmed with a specific assay such as
ProCISE. Then, combinations of standard and immunoproteasome targeting could be more
accurately studied. However, from a therapeutics perspective, this data indicates that
additional targeting of the immunoproteasome does not enhance the efficacy of BTZ or
MRZ.
It is unknown whether upregulation of immunoproteasomes could be a mechanism of
resistance to standard proteasome inhibitors in GBM. A past study demonstrated that a
specific inhibitor of β1i, IPSI-001, was able to induce death in myeloma cells resistant to
BTZ [63]. Though ONX-0914 was not effective in the current study, it would be interesting
to study whether it can induce death in GBM cells that are resistant to BTZ, such as those
that have been continuously exposed to increasing doses of BTZ or MRZ to select for
resistant cells.
Targeting of regulatory cap elements: PA28γ
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Though the proteasome has several alternative regulatory cap subunits, PA28γ is
relevant to this work because it has been found to be expressed at high levels in the brain
[35], and reports indicate that it may regulate important cellular functions such as ubiquitinindependent degradation of select proteins including the cell cycle regulator p21 [36]. For
these reasons, I hypothesized that PA28γ might play a role in GBM.
Though PA28γ was expressed in GBM cell lines, knocking it down with siRNA did
not enhance sensitivity to BTZ or MRZ (Fig. 2.14). This is likely because BTZ and MRZ
cause strong inhibition of the catalytic activity of the proteasome, making targeting of a cap
subunit redundant. Overall, additional targeting of PA28γ did not enhance the therapeutic
efficacy of BTZ or MRZ.
Chapter 2 Future Directions: The future of proteasome targeting in GBM
Experiments with proteasome inhibitors such as BTZ and MRZ have provided
evidence that manipulation of the proteasome can be a useful strategy in cancer therapy.
Looking forward, several other methods of targeting the ubiquitin-proteasome system are
being developed that offer potential in two key areas: improved tolerability and increased
specificity of targeting (Fig. 5.1).
Studies have frequently suggested that green tea has cancer preventative properties
[164]. An interesting line of investigation has revealed that the polyphenol epigallocatechin3-gallate (EGCG) is an inhibitor of the proteasome. Specifically, EGCG inhibited
chymotrypsin-like proteasome activity in purified proteasomes and Jurkat leukemia cells at
doses that were suggested to be achievable in the serum of people who consumed green tea
[165]. As a consequence, EGCG caused accumulation of p27 and cell cycle arrest in Jurkat
cells. Since then, synthetic EGCG analogs have also been investigated for their proteasome
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inhibitory abilities [166]. This line of work is an interesting example of a proteasome
inhibitor from a natural product that appears to be non-toxic. Due to its tolerability, EGCG is
frequently considered to have potential as a cancer preventive agent. Future experiments will
reveal whether EGCG can augment other types of therapy specifically by inhibiting the
proteasome. Notably, EGCG has been shown to antagonize BTZ, preventing it from
inhibiting the proteasome [152]. Therefore, consumption of green tea polyphenols is
contraindicated for patients receiving BTZ. The potential of EGCG lies in augmentation of
other therapeutic strategies in a highly tolerable manner.
Another strategy for inhibition of the ubiquitin-proteasome pathway involves
targeting of the ubiquitin conjugating system. This process can be targeted at numerous steps.
Inhibitors of E1 activating enzymes have developed, including PYR-41, an agent that inhibits
formation of the thioester bond between ubiquitin and the active site cysteine of E1 ubiquitin
activating enzymes [167]. This agent blocks ubiquitination in cells, which is a fairly broad
mechanism, as the E1 enzyme is responsible for all ubiquitin activation and is not specific for
certain substrates.
More finely targeted inhibitors target E3 ubiquitin ligases. Cullins, which are
components of cullin-RING E3 ubiquitin ligases, are modified by the addition of NEDD8, a
small ubiquitin family member that is activated in a process similar to that of ubiquitin. The
addition of NEDD8 to cullins is necessary for their activation. Inhibitors have been designed
to target the NEDD8 activating enzyme, which therefore prevents activation of cullin-RING
E3 ligases [168]. MLN4924, an inhibitor of NEDD8 activation, was shown to radiosensitize
breast cancer cells in a manner dependent on p21 accumulation after cullin-RING ligase
inhibition [169].
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Figure 5.1: Targeting the ubiquitin-proteasome pathway. Inhibitors of the
proteasome used in this study (highlighted in red, bold text) included inhibitors of the
standard proteasome (BTZ and MRZ), immunoproteasome (ONX-0914) and PA28γ
(siPA28γ). Other strategies for inhibiting protein degradation include inhibition of
ubiquitin activating enzymes (PYR-41), inhibitors of E3 ligase substrate recognition,
inhibitors of neddylation (MLN4924), and natural inhibitors of the proteasome (EGCG,
epigallocatechin gallate) Abbreviations: N, NEDD8; U, ubiquitin.
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Attempts have been made to develop more direct inhibitors of E3 ligases that
interfere with their ability to recognize and bind substrates [170, 171]. Since E3 ligases are
responsible for specific substrate recognition and ubiquitylation, it is possible that targeting
them could be honed for more specific inhibition of protein degradation. For example, S
phase kinase-associated protein 2 (Skp2) has been shown to recognize both p21 and p27 and
target them for proteasomal degradation as part of E3 ligase SCF (Skp1-Cullin1-F-box
protein) complexes [172, 173]. Therefore, inhibition of this E3 ligase complex could prevent
degradation of these important cell cycle regulators.
Notably, targeting the ubiquitin conjugating pathway would only inhibit ubiquitindependent proteasome degradation; the proteasome is also capable of degrading some
proteins independently of ubiquitin conjugation [174]. It will be interesting to determine
whether more refined targeting of protein degradation can reduce toxicity while maintaining
potent anticancer activity.
Perhaps most intriguing in the future of proteasome targeting is the possibility of
specifically targeting the proteasomes that are assembled in response to the increased
proteotoxic stress frequently present in cancer cells. A recent study in yeast reported a heat
shock-induced protein, Adc17, that was specifically involved in assembly of proteasome
regulatory caps under stress conditions [175]. Though no human homolog for Adc17 was
identified by sequence analysis, it is possible that a functional homolog exists. Screens in
mammalian cells that identify factors necessary for assembly of proteasomes specifically
under stress conditions could provide intriguing targets for specific targeting of stressinduced proteasomes in cancer cells.
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My work in this report has demonstrated that BTZ and MRZ strongly suppress
proteasome activity, leading to accumulation of ubiquitinated substrates. Concordant avenues
of investigation have presented new tools for inhibiting the ubiquitin-proteasome system,
such as natural extracts and specific inhibitors of the ubiquitin conjugating system. Since
strength and duration of proteasome inhibition have been linked to the anticancer efficacy of
proteasome inhibitors such as BTZ and MRZ [61], new inhibitors must be tested to ensure
they are capable of achieving desired effects on the function of this pathway. I have
investigated some alternative targeting strategies, including an immunoproteasome inhibitor
and knockdown of PA28γ, and have concluded that these strategies do not induce GBM cell
death as single agents, nor do they enhance the activity of BTZ or MRZ. New agents should
be tested in a similar manner in GBM.
Chapter 3 Discussion
Death induction by proteasome inhibitors in GBM
Having studied the dynamics with which BTZ and MRZ inhibited proteasome
activity in GBM cells, I went on to investigate how that inhibition translated into effects on
cell death. I examined multiple readouts of death and growth inhibition in GBM cells treated
with proteasome inhibitors: viability by trypan blue exclusion, DNA fragmentation by
propidium iodide staining, and colony growth in soft agarose (Fig. 3.1-3).
Proteasome inhibitors decreased viability and increased DNA fragmentation in GBM
cells. BTZ caused these effects at lower doses than MRZ, which is consistent with my
previous observations that BTZ caused longer-lasting proteasome inhibition than MRZ.
Overall, however, GBM cells were sensitive to both BTZ and MRZ at reasonably low doses
in the nanomolar range. These experiments establish that proteasome inhibition potently
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induces death in GBM cells. Examination of the growth of colonies in soft agarose also
showed inhibition of colony growth by BTZ and MRZ.
Proteasome inhibitors have been shown to induce caspase-dependent death in a
variety of cancer cell types [66-68]; however, the dependence of proteasome inhibitors on
caspases in GBM has not yet been established. This information is important for determining
biomarkers of drug efficacy and for anticipation of mechanisms of drug resistance.
Therefore, I set about examining the three initiator caspases: caspases 2, 8, and 9. I observed
cleaved caspase bands, representing the initial steps of caspase activation, for all three
initiator caspases after proteasome inhibition (Fig. 3.4). Activity of the executioner caspases
3/7 was detected 16 and 24 h following proteasome inhibitor treatment. To test the
hypothesis that caspase activation was an essential part of proteasome inhibitor-mediated cell
death, I pre-treated cells with a pan-caspase inhibitor, z-VAD-fmk. This agent blocked nearly
all the DNA fragmentation induced by both BTZ and MRZ (Fig. 3.5). Together, this data
indicates that death induction by proteasome inhibitors is caspase-dependent in GBM, and all
three initiating caspases may play a role in this death.
Activation of caspase 2 by proteasome inhibitors in GBM
I observed that caspase 2 was cleaved earlier than the other initiator caspases after
proteasome inhibitors. Therefore, I became interested in the role caspase 2 may be playing in
proteasome inhibitor-induced apoptosis in GBM. Caspase 2 can be activated following heat
shock and DNA damage [73, 76, 176, 177], but activation of this caspase has not been
extensively studied in GBM. The signals initiate recruitment of caspase 2 to the PIDDosome,
a complex including PIDD and RAIDD, where caspase 2 CARD domains interact and
catalytic processing occurs to activate caspase 2 [73, 178, 179]. Caspase 2 goes on to cleave
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Bid, which leads to mitochondrial permeabilization and downstream activation of caspase 9
[75, 76]. Caspase 2 has been described as a tumor suppressor, as cells deficient in caspase 2
are resistant to DNA damaging agents and do not properly initiate apoptosis after cell cycle
inhibition [77]. These background studies indicate that activation of caspase 2 by proteasome
inhibitors would be a logical mechanism of death.
I wanted to be sure that the cleavage of caspase 2 that I observed was truly indicative
of activation, as cleavage can sometimes occur in a manner not associated with activation.
Therefore, I studied another step in caspase 2 activation; induced proximity that occurs as
caspase 2 is recruited to the PIDDosome. This step is a definitive step in the activation
process, and can be measured using the Venus bimolecular fluorescence protein attached to
caspase 2 CARD domains [178]. I used this system as a second readout, in addition to
cleavage on Western blot, to show that caspase 2 is activated quickly after proteasome
inhibitor treatment, especially with MRZ (Fig. 3.6).
Though caspase 2 was definitely activated, experiments with caspase 2 knockdown
revealed that it was not essential for death induction by BTZ or MRZ. In fact, cells stably
expressing caspase 2 shRNA actually had slightly increased cleavage of caspase 9, caspase
3/7 activity, and DNA fragmentation (Fig. 3.8). This was very interesting given that it was
the opposite of what was expected. One piece of evidence that caspase 2 serves a different
purpose than the other initiator caspases is the kinetics of caspase activation. The Venus
BiFC model indicates that caspase 2 is recruited to the PIDDosome as early as 1 h to 2 h.
However, activation of other caspases does not occur until 12 h to 24 h, and DNA
fragmentation is seen at even later times (24 h to 48 h). This could have interesting
implications for alternative roles of caspase 2, perhaps even in cell cycle checkpoints in a
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manner that is more ameliorative than death inducing. Data from caspase 2-deficient mice
indicates that caspase 2 has opposing roles in death induction in different cell lineages.
Oocytes and lymphoblasts from caspase-2 deficient mice were more resistant to death, while
sympathetic neurons from these same mice were more susceptible to death following
withdrawal of nerve growth factor [180]. The conflicting roles of caspase 2, particularly
evidence that it can protect neurons from death, lends support to the idea that caspase 2 could
also be protective in GBM cells. In the case of GBM cells, caspase 2 is not required for death
induction by proteasome inhibitors.
Induction of death by caspase 9 after proteasome inhibition in GBM
I then examined the importance of caspases 8 and 9, which were both activated
around 12 h following proteasome inhibition. I used 2 methods to examine the importance of
caspases 8 and 9: chemical inhibitors that use substrate specificity to block caspase protease
activity and shRNA specifically targeting either caspase 8 or 9. These experiments revealed
that inhibition of caspase 9 blocked activation of caspase 8, and also blocked some DNA
fragmentation in both models. This indicates that caspase 9 is at the top of the caspase
hierarchy after treatment with BTZ and MRZ in GBM (Fig. 5.2).
There were some differences between the chemical inhibitors and shRNA that should
be noted. Mainly, chemical inhibitors of both caspase 8 and caspase 9 blocked a significant
portion of the DNA fragmentation induced by BTZ and MRZ. However, when I repeated
these experiments with shRNA, only a small portion of DNA fragmentation was blocked,
and only by shCASP9 and not by shCASP8. One reason for this difference is the lack of
specificity of the chemical inhibitors. Caspases have overlapping cleavage specificities, so
the inhibitors recognize different caspases to varying degrees [144]. For instance, the peptide
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used for caspase 8 (IETD) is also recognized by the executioner caspases 3 and 6. Therefore,
it is logical that this inhibitor would have a strong protective effect on DNA fragmentation.
Notably, the caspase 8 inhibitor has a very low affinity for the other initiator caspases, which
is why it is still useful for experiments that seek to determine the apical initiating caspase in
GBM. Similarly, the caspase 9 inhibitor (LEHD) has some affinity for the executioner
caspases, but much lower affinities for the other initiators [144]. This explains the strong
effects of these inhibitors on DNA fragmentation suppression, but also indicates that they are
still valid tools due to their relative specificity as far as the initiator caspases are concerned.
In fact, blockade of the executioner caspases by these inhibitors will prevent downstream
cleavage of initiator caspases by activated executioner caspases, which adds reassurance that
the effects I observed with these inhibitors on initiator caspase cleavage are really due to
initiating and not late events.
With the shRNA, there were differences between early (24 h) and later (48 h) death in
cells expressing shCASP8 or shCASP9 (Fig. 3.14-15). At 24 h, shCASP9 suppressed death
by both BTZ and MRZ. Interestingly, shCASP8 also suppressed death, but only in cells
treated with MRZ, not BTZ. This is consistent with previous studies in leukemia that have
found an increased dependence on caspase 8 for MRZ [68]. However, only caspase 9
prevented death by both inhibitors. This could have interesting implications for the intrinsic
sensitivity of brain-derived cells to death induction by specific caspases.
Caspase 9 has a notable connection to brain development and apoptosis after brain
injury. Caspase 9 homozygous knockout mice usually die before birth and are marked by
enlarged cerebrums, indicating defective apoptosis during brain development [181]. Though
genes involved in caspase 9 activation, such as Apaf-1, have been found to be repressed in
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the brain as development progresses, insults such as traumatic brain injury have been shown
to cause re-expression of this pathway and subsequent caspase 9-dependent cell death [182].
This evidence, particularly the marked effects on brain development in caspase 9-deficient
mice, supports the hypothesis that brain-derived cells, such as GBM cells, may be more
susceptible to caspase 9-dependent apoptosis versus death induced by other caspases.
A final point that needs to be addressed concerning the experiments with caspase 8
and 9 shRNA has to do with the fact that after 48 h, there were only minor effects on death in
the shCASP9 cells (Fig. 3.15). This would seem to indicate that the effects of caspase 9 are
not particularly strong. However, there is precedent for the idea that reduction in the main
death-inducing caspase can be compensated for by other caspases. For example, a study by
Zheng et al. of a Fas agonistic antibody, Jo2, showed that mitochondrial permeability and
activation of caspases 9 and 3 were necessary events for death induction in hepatocytes after
treatment with Jo2 [183]. However, hepatocytes from mice deficient in caspases 9 or 3 were
not protected from Jo2-induced apoptosis. In fact, apoptosis still occurred, and it was due to
activation of caspases 2, 6, and 7, which were not detected in wild-type mice. Interestingly,
the activation of compensatory caspases was still downstream of mitochondrial membrane
permeability in caspase 3 and 9 deficient mice, indicating that the requirement for this event
remained the same.
This study illustrates that the caspase pathways exhibit flexibility, and activation of
compensatory caspase pathways is possible in cases of caspase deficiency. While this could
explain the blunted effects on death that I observed after 48 h in shCASP8 and 9 cells, it is
notable that early events (24 h) were still dependent on caspase 9. Therefore, failure of
activate caspase 9 at the very least will delay apoptosis, and will prohibit death completely in
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some cells. Together, my data indicates that compensatory pathways are possible, but the
strongest death induction occurs through cleavage of caspase 9.
Bcl-XL protection from proteasome inhibitor-induced death, but not caspase 9 cleavage
As a method for further probing the role of caspase 9 in proteasome inhibitor-induced
death, I overexpressed the anti-apoptotic Bcl-2 family member Bcl-XL in LN18 GBM cells. I
expected Bcl-XL to maintain mitochondrial integrity, preventing activation of caspase 9 and
subsequent apoptosis. While Bcl-XL did reduce DNA fragmentation in response to
proteasome inhibitors (Fig. 3.18), it did not prevent decreases in mitochondrial membrane
potential or cleavage of caspase 9 after proteasome inhibition (Fig. 3.19). Notably, both
caspase 9 cleavage and DNA fragmentation were prevented in Bcl-XL overexpressing cells
treated with staurosporine, which activates the mitochondrial pathway of apoptosis.
The lack of protection against caspase 9 cleavage in Bcl-XL overexpressing cells
could simply mean that the degree of Bcl-XL overexpression is inadequate for preventing
these events. However, it is possible that overexpression of this protein has other unintended
effects on cells besides protection of the mitochondrial membrane. Bcl-2 family members
have also been shown to localize to the endoplasmic reticulum (ER), and Bcl-XL has been
shown to cause release of calcium from the ER [184, 185]. As a regulator of intracellular
calcium flux, Bcl-XL could have numerous effects such as stimulating mitochondrial energy
production or potentially activation of calpains [185]. Calpains are a family of proteases that
have been shown to activate caspases in response to ER stress [186]. These studies
demonstrate the Bcl-XL has complex functions that go beyond its regulation of
mitochondrial membrane permeability. Overexpressing Bcl-XL can affect all of these
aspects, and future investigation of alternative roles of Bcl-XL may lend insight into why
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cells overexpressing this protein are protected from proteasome inhibitor-induced apoptosis
independently of mitochondrial membrane protection and cleavage of caspase 9.
The protective effect of thiol reducing agents against proteasome inhibitor-induced
death in GBM.
Given previous reports that generation of ROS is important for proteasome inhibitormediated death [47, 68, 82, 84], I investigated ROS induction as well as the effect of
antioxidants in GBM cells treated with BTZ or MRZ. Treatment with NAC or DTT blocked
caspase activation and cell death in a manner independent of GSH (Fig. 3.23-24). Also,
despite previous reports that NAC directly inactivates BTZ [187], I found that both BTZ and
MRZ were still able to proteasome activity in cells pre-treated with NAC (Fig. 3.25).
Therefore, NAC and DTT block proteasome-inhibitor induced death in a manner independent
of GSH or direct inactivation of proteasome inhibitors.
It has also been reported that proteasome inhibitors cause amino acid starvation,
particularly through depletion of the amino acids cysteine and asparagine in MEFs [153]. In
that study, supplementing with cysteine and asparagine was protective against the
proteasome inhibitor MG132. I hypothesized that NAC may be protecting cells from
proteasome inhibitors by flooding cells with cysteine, rescuing them from starvation.
However, amino acid levels were not reduced following proteasome inhibition in LN18 cells,
and additional supplementation with asparagine had minimal effects on proteasome inhibitorinduced death (Fig. 3.26-27). Therefore, I concluded that amino acid starvation was not a
likely mechanism of proteasome inhibitor efficacy in GBM.
Alternatively, NAC and DTT impact thiol levels to create a reduced cellular
environment. Given their broad effects on cellular reduction potential, NAC and DTT may
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affect many proteins in stress response and cell death pathways, such as caspases and
components of caspase activating complexes. Thiol modulation can also impact cellular
stress responses, as DTT and NAC have been shown to attenuate heat shock death in
endothelial cells, whereas GSH did not prevent death [148]. DTT has also been found to
inhibit the heat shock response and decrease translation by increasing phosphorylation of
eukaryotic initiation factor 2α [188, 189]. The way NAC and DTT modulate the cellular
reducing environment and influence stress pathways may provide insight into the mechanism
by which they protect cells from proteasome inhibitor-induced death.
Chapter 3 Future Directions: Looking at indicators of sensitivity to caspase 9-depentent
apoptosis following proteasome inhibition in GBM.
Since caspase 9 is the initiating caspase in GBM cells treated with proteasome
inhibitors, examination of factors related to caspase 9 activation could serve as biomarkers of
drug efficacy as well as help anticipate drug resistance. For example, mitochondrial
membrane permeability or cleavage of caspase substrates could be examined in tumors to
evaluate whether BTZ and MRZ are exerting effects at the molecular level in GBM patients.
As for mechanisms of resistance, factors that mediate mitochondrial permeability
could impact caspase 9 activation, and therefore efficacy of proteasome inhibitors. Bcl-2 and
Bcl-XL, which are anti-apoptotic regulators of mitochondrial membrane integrity, have been
found to be expressed in GBM and other cancer types, which could be an important
mechanism of resistance to proteasome inhibitors [112]. Drugs have been developed to
inhibit these anti-apoptotic proteins, such as ABT-737, a therapeutic agent that mimics the
BH3 proteins that are natural antagonists of pro-apoptotic Bcl-2 family members [190].
Targeting Bcl-2 and Bcl-XL induces apoptosis in GBM cell lines, suggesting these proteins
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are important mediators of apoptosis in GBM [113]. High levels of these proteins in a GBM
patient would suggest possible resistance to MRZ and BTZ, and would encourage the use of
therapeutics like ABT-737 that would ameliorate the effects of high levels of these antiapoptotic proteins.
As I mentioned earlier, my data concerning the protective effects of NAC and DTT
also suggests the potential for future studies into how modulation of cellular stress by these
agents could be involved in protection from proteasome inhibitor-induced death. This data
also has clinical implications. Vitamin C and other antioxidants have already been shown to
prevent BTZ efficacy in myeloma [151], and thiol-rich agents such as NAC and DTT that
alter the reducing environment in cells should also be evaluated for contraindications.
Additionally, this work suggests that GSH, but not NAC, may be an appropriate treatment for
the peripheral neuropathy associated with BTZ treatment [102], as it does not attenuate
proteasome inhibitor efficacy.
Chapter 4 Discussion
Accumulation of proteasome substrates in orthotopic brain tumors after BTZ and
MRZ treatment.
A main goal of this work was to establish the ability of BTZ and MRZ to have
functional effects on proteasomes in orthotopic brain tumors. These experiments answered
important questions about BBB permeance that have not been adequately addressed by
studies that used subcutaneous models [80, 98] or by trials where biomarkers of drug efficacy
were not reported [97]. Both BTZ and MRZ caused accumulation of the proteasome substrate
p21 in orthotopic brain tumors, while only MRZ increased p27 (Fig. 4.1-2). This indicates
that MRZ may have a stronger effect in vivo, particularly on specific substrates like p27.
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Interestingly, MRZ did not cause longer lasting proteasome inhibition than BTZ in
vitro, but data from in vivo experiments suggests a different dynamic in an orthotopic animal
model, perhaps due to better BBB penetration of MRZ in tumor bearing mice. Importantly,
these experiments demonstrate that BTZ and MRZ do have the ability to be delivered to
brain tumors, which was uncertain as past studies of mice without brain tumors, and therefore
with intact BBB, have indicated that these drugs may not reach brains [99]. This work
emphasizes the importance of using relevant in vivo models that represent the actual clinical
condition as closely as possible. Also, given the negative clinical trial results with BTZ in
GBM, it is especially important to monitor biomarkers of drug function.
Proteasome inhibition combination therapy: targeting IAPs
Another step toward establishing the clinical potential of BTZ and MRZ is designing
rational combination strategies to enhance therapeutic efficacy. The decision to target IAPs
was based on the observation that MRZ induced greater cleavage of initiator caspases, but
not stronger death, compared to BTZ (Fig. 4.3). IAPs can bind to active caspases, particularly
caspases 9, 3, and 7, and inhibit apoptosis [114]. Therefore, I hypothesized that MRZ may
increase IAPs, inhibiting cell death even in the presence of caspase activation.
I found that neither MRZ or BTZ increased protein levels of XIAP (Fig. 4.4).
However, even though protein levels were not altered, there is still a possibility that IAPcaspase interactions were somehow enhanced in MRZ-treated cells. To discover if targeting
IAPs was a useful strategy for enhancing efficacy of MRZ, I utilized mimetics of Smac, a
cellular inhibitor of IAPs. The Smac mimetics birinapant and LCL-161 increased death in
combination with both BTZ and MRZ (Fig. 4.5), suggesting an overall role of IAPs in
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preventing the efficacy of proteasome inhibitors, though it demonstrated that this effect was
not unique to MRZ.
Though birinapant and LCL-161 have been shown to cause ubiquitination and
degradation of IAPs [156], I did not observe changes in IAP levels following treatment. This
raised concerns that the drugs were not acting as previously described. Therefore, I silenced
XIAP and cIAP-1 with siRNA to see if specific targeting of these proteins enhanced
combination efficacy. Knockdown of cIAP-1 and XIAP did not enhance the efficacy of BTZ
and MRZ (Fig 4.6). This suggests that either other IAPs besides XIAP and cIAP-1 are
targeted by birinapant and LCL-161, or off-target effects of these agents are responsible for
their combination effects. Since birinapant and LCL-161 do enhance death induction by
proteasome inhibitors, future studies are needed to understand how these drugs are
functioning to yield this effect.
Proteasome inhibition combination therapy: targeting HDACi
I also examined targeting of HDACi in combination with proteasome inhibitors. The
combination of BTZ with vorinostat in GBM has shown promise in preliminary in vitro
studies [95], but a clinical trial of this combination that did not report molecular markers of
efficacy for either agent failed to prevent disease progression [97].
In this study, I found that MRZ and BTZ synergized in GBM cells with the panHDACi vorinostat and panobinostat, but not with the class I HDACi entinostat (Fig. 4.7-9,
Table 1.1). Therefore, targeting of class I HDACs is not sufficient for combination effects. I
also investigated areas where the mechanisms of proteasome inhibitors and HDACi might
intersect, and I found that vorinostat decreased mRNA of the proteasome catalytic subunit β5
(Fig. 4.11). This decrease in mRNA was accompanied by functional changes, as both
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vorinostat and panobinostat decreased proteasome activity, alone and in combination with
proteasome inhibitors (Fig. 4.12-13). The decrease in mRNA is consistent with past
experiments in leukemia [139]. Upregulation of β5 expression has been shown to cause
resistance to proteasome inhibitors [106], so the fact that HDACi suppress expression could
have interesting implications for preventing resistance to BTZ and MRZ.
I also investigated the combination of BTZ and MRZ with vorinostat in an orthotopic
model of GBM. Given strong in vitro data from past studies and the data from this current
study, further examination of the reason for the disappointing clinical result is warranted [95,
96]. Also, MRZ has not been tested with vorinostat in vivo in GBM. Based on my result that
proteasome inhibitors induce caspase 9-dependent death in GBM, and also the fact that the
combination of BTZ or MRZ with vorinostat enhances cleavage of caspase 9, I chose to
examine cleavage of the executioner caspase 3, as well as cleavage of the caspase substrate
lamin A in tumors of mice treated with proteasome inhibitor and HDACi combinations.
Though there was a lack of single-agent efficacy for any of the drugs in vivo, cleaved lamin
A was notably increased in tumors from mice treated with the combinations of BTZ or MRZ
with vorinostat (Fig. 4.17). There was a trend toward increased lamin A cleavage in mice
treated with vorinostat plus MRZ versus the combination with BTZ, indicating once again
that MRZ may be exerting a stronger effect than BTZ in vivo. Though cleaved caspase 3
staining was weak, it is notable that the only samples that showed any positivity were tumors
treated with MRZ and vorinostat (Fig. 4.16). It is possible that MRZ shows increased
efficacy in this combination due to stronger effects on proteasomes, as indicated by its effects
on proteasome substrates in brain tumors.
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Chapter 4 Future Directions: Confirming effects of proteasome inhibitors on survival of
orthotopic GBM models.
My initial experiments demonstrate that BTZ and MRZ are capable of causing
accumulation of proteasome substrates in orthotopic brain tumors. More definitive
experiments are necessary to confirm this, as well as to determine whether there is truly a
difference between BTZ and MRZ in vivo. One way to measure this would be to use
radiolabeled drug to confirm delivery to brain tumors. Previous studies have used similar
systems, but they have generally focused on delivery to other organs [99]. Another
possibility for monitoring proteasome activity uses a technique in which a degradationtargeting is fused to a green fluorescence protein. Vlashi et al. demonstrated that a protein
constructed in this manner accumulated in the absence of proteasome activity, allowing for
fluorescence monitoring of proteasome activity in live cells [191]. GBM cells could be
modified to express this protein, allowing for analysis of proteasome activity in brain tumors
that have been treated with proteasome inhibitors.
My in vitro data also supports further investigation of newer HDACi in vivo.
Panobinostat was effective at lower doses than vorinostat in vitro (nanomolar doses versus
micromolar). This increased potency should be examined in vivo. Panobinostat is already
being studied in the clinic for high grade glioma in combination with the angiogenesis
inhibitor bevacizumab [192], further indicating its relevance for treatment of brain tumors.
This study focused on molecular markers of death in brain tumors. However, to
further establish the clinical relevance of these agents and combinations, future experiments
are needed to examine whether these agents reduce tumor size and enhance survival of mice.
To examine tumor size, U87 cells expressing luciferase can be injected into mice, which
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allows for imaging of tumor size as treatment progresses. This non-invasive imaging allows
for monitoring of direct tumor effects while also looking at overall survival of the mice.
As a final piece of evidence supporting these agents clinically, it is possible to use
different tumor models that are considered to be more representative of clinical GBM.
Though U87 cells are commonly used to generate xenograft tumors, there is concern over the
fact that these cells were isolated over 40 years ago, and long-term culture may make them
less similar to the clinical disease state [193]. More recent studies have focused on isolation
of glioma stem cells from patient specimens; that is, cells that display multipotency and the
ability to recapitulate brain tumors from single cells [194]. Using glioma stem cells to
establish orthotopic tumors allows for testing of therapeutic agents on a putative stem cell
population, which is thought to be more resistant to therapy, and which has also been
described as a main cause of tumor recurrence [195]. The evidence for the clinical relevance
of BTZ and MRZ would be bolstered by experiments with combination agents with increased
potency in relevant animal models that utilize cancer stem cells and measure effects on tumor
size and survival.
Concluding remarks
The goal of this study was to establish the clinical relevance of proteasome inhibitors
in GBM by first determining the optimal subunits for targeted therapy, then by defining the
mechanism of apoptosis induction for optimal monitoring of drug efficacy and prediction of
resistance, and finally by establishing the properties of these agents in a relevant orthotopic
brain tumor model. By answering these questions, I have established a framework for future
clinical experiments.

141

Targeting alternative proteasome components, such as the immunoproteasome and
PA28γ, did not enhance the effects of BTZ and MRZ. Treatment with BTZ or MRZ was
sufficient to induce death in GBM cells without combined targeting of other pathway
components.
Having determined that targeting the standard proteasome with BTZ and MRZ was an
optimal strategy, I then performed experiments that allowed me to ascertain that these agents
induce caspase 9-dependent apoptosis in GBM cells. This information can be used to monitor
treatment efficacy in future studies, such as by examination of mitochondrial permeability
and cleavage of caspase substrates. Additionally, this information opens the door for future
studies into whether factors that limit caspase 9 activation, such as overexpression of antiapoptotic Bcl-2 family members, can serve as biomarkers for predicting resistance to
proteasome inhibitors in GBM.
I also determined that proteasome inhibitor efficacy was blocked by the cellular
reducing agents NAC and DTT, but not by GSH. Notably, NAC and DTT blocked early steps
in apoptosis, including release of cytochrome C from the mitochondria and caspase cleavage.
NAC and DTT potentially perform this function through as-yet undefined changes in the
cellular reducing environment or stress responses. This information also has important
implications for the clinical use of proteasome inhibitors, as antioxidants are being examined
as supplements that may reduce side effects, particularly peripheral neuropathy induced by
BTZ. My work suggests that GSH could be safe for co-administration with proteasome
inhibitors, as it does not interfere with drug efficacy. However, other agents with reducing
properties, such as NAC, should not be used.
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Finally, I presented results that establish the potential of BTZ and MRZ in a relevant
orthotopic model. I showed that both agents cause accumulation of proteasome substrates in
brain tumors, with MRZ having slightly stronger effects. I also demonstrated that the
combination of vorinostat with proteasome inhibitors effects molecular markers of death in
brain tumors, especially in tumors from mice treated with MRZ and vorinostat. Together,
these results suggest a need for future examination of these agents in clinical trials that
carefully monitor the molecular biomarkers of drug efficacy.
This study demonstrates that targeting the proteasome is a potent strategy in GBM.
Future studies of alternative methods of proteasome targeting, such as inhibitors of E3 ligases
or stress-induced proteasome induction, could provide more tolerable and specific options for
targeting protein degradation. Additionally, this study provided ideas for development of
biomarkers of drug efficacy and resistance that are based on the mechanism of death
induction by caspase 9 that I have defined here. Finally, the in vivo experiments I presented
here represent a basis for more exhaustive investigation of proteasome inhibition and survival
enhancement achieved by proteasome inhibition therapy in various models of GBM. The
work presented here, along with the future experiments, provides a detailed examination of
the kinetics and mechanism of death induced by proteasome inhibitors in GBM cell lines and
orthotopic tumors.
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Chapter 6
Materials & Methods
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Cell Culture and Reagents
All cells were maintained in an incubator at 37 °C with 5% CO2. GBM cell lines
(LN18, SNB19, U87, and U251) were obtained from ATCC and were maintained in
DMEM/F12 media with 10% FBS, 1% penicillin and streptomycin, and 1% L-glutamine.
Cells were authenticated by the Characterized Cell Line Core Facility at MD Anderson
Cancer Center using the short tandem repeat method. Normal human astrocytes (NHA,
E6/E7/TERT immortalized) were obtained from Kenneth Aldape (MD Anderson Cancer
Center, Houston, TX) and were maintained in DMEM/F12 media with 10% FBS, 1%
penicillin and streptomycin, 1% L-glutamine, 0.2 µg/mL puromycin, and 10 µg/mL
blasticidin. PA28γ-/- MEFs were provided by Lance Barton (Austin College, Sherman, TX).
PA28γ-/- MEFs were cultured in DMEM media supplemented with 10% FBS, 1 mM sodium
pyruvate, 50 µM β-mercaptoethanol, 2 mM L-glutamine, 1X non-essential amino acids, and
1% penicillin and streptomycin. Caspase 2-/- MEFs (E1A/Ras immortalized) were provided
by Lisa Bouchier-Hayes (Baylor College of Medicine). Caspase 2-/- MEFs were cultured in
DMEM media with 10% FBS, 2 mM L-glutamine, 1% penicillin and streptomycin, 1X
sodium pyruvate, 1X non-essential amino acids, and 55 µM β-mercaptoethanol.
BTZ was obtained from LC Labs (Woburn, MA) and MRZ was provided by Nereus
Pharmaceuticals (San Diego, CA).

Proteasome Activity Assay
Cells incubated with indicated treatments were harvested by brief incubation with
0.05% trypsin. Cells were pelleted by centrifugation (1,700 rpm for 3 min) and pellets were
washed 1X in ice cold PBS. Cells were resuspended in 20S proteasome lysis buffer (20 mM
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Tris, pH 7.5, 0.1 mM ethylenediaminetetraacetic acid, 20% glycerol, and 0.05% NP-40
supplemented each time with fresh 1 mM β-mercaptoethanol and 1 mM adenosine
triphosphate). Cells were lysed by freezing and thawing 3X on dry ice. Samples were then
spun for 1 min at 12,000 rpm. Samples were aliquoted to duplicate wells (100 µL/well) of a
black 96-well plate. Next, 98 µL substrate buffer (50 mM HEPES, pH 7.5, and 50 mM
EGTA, pH 7-8) were added to each well along with 2 µL fluorogenic substrate: suc-LLVYamc for chymotrypsin-like activity or z-LLE-amc for caspase-like activity (AG Scientific,
San Diego, CA, USA), and boc-LRR-amc for trypsin-like activity (Enzo Life Sciences, Inc.,
Farmingdale, NY, USA). After 1 h incubation with fluorogenic substrates, fluorescence was
read on a Gemini EM Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) at an
excitation of 380 nM and an emission of 460 nM. For experiments that indicate they were
standardized to DMSO, all samples were divided by the fluorescence value for control
(DMSO treated) cells.

Western Blotting
Cells were lysed for 1 h at 4 °C in Triton X-100 lysis buffer (PBS containing 1%
Triton X-100, 25 mM Tris, pH 7.5, and 157 mM NaCl) supplemented with a cOmplete Mini
protease inhibitor cocktail tablet (Roche, Basel, Switzerland) and 1 mM glycerol phosphate,
1 mM NaF, and 1 mM NaOrthoV, with the exception of lysates for analysis of histones
(please see “Analysis of acetylated and total histone levels” section). Debris was pelleted by
spinning samples for 20 min at 12,000 rpm at 4 °C, and protein concentrations were
determined by Bradford Assay (Bio-Rad, Hercules, CA, USA).
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Proteins were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto polyvinylidene fluoride membranes. After blocking for 1
h at room temperature in 5% milk or bovine serum albumin in TBS-T, membranes were
incubated with 1:1,000 dilutions of the following primary antibodies: LMP7 (Abcam,
Cambridge, England), actin (Sigma, St. Louis, MO, USA), β5 (Enzo, Farmingdale, NY,
USA), caspase 8, caspase 9, LC3B, tubulin (Cell Signaling, Beverly, MA, USA), acetylated
histone H3, caspase 2, total histone H3 (EMD Millipore, Billerica, MA, USA), cytochrome
C, p27 Kip1, XIAP (BD, San Jose, CA, USA), Bcl-XL, cIAP-1, ubiquitin (Santa Cruz,
Dallas, TX, USA) and PA28γ (provided by Lance Barton, Austin College). Membranes were
then washed 3X with TBS-T before being incubated with appropriate horseradish peroxidase
conjugated secondary antibodies (mouse and rabbit: GE Healthcare, Buckinghamshire,
England; rat: Cell Signaling, Beverly, MA, USA). Chemiluminescent visualization of bands
was performed using a Kodak film developer (Rochester, NY, USA). Densitometry was
evaluated using Image J software (National Institutes of Health, Bethesda, MD).

DNA Fragmentation
Cells were harvested by brief incubation with 0.05% trypsin. Cells were pelleted by
centrifugation (1,700 rpm for 3 min) and washed 1X in PBS. Cells were fixed in 70% ethanol
by resuspending cell pellets in 300 µL ice cold PBS, then adding 700 µL ice cold ethanol
dropwise with gentle vortexing. After fixation for at least 24 h, samples were centrifuged
(1,700 rpm for 3 min), washed 1X in PBS, and resuspended in a PBS solution containing 50
µg/mL propidium iodide and 100 µg/mL ribonuclease A. After incubation for 30 min to 1 h
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with propidium iodide, the cell cycle was analyzed on the FL-3 channel of a flow cytometer
(FACSCalibur™, BD Biosciences, San Jose, CA, USA).

Proteasome Activity in Cell Lysates
LN18 cells were resuspended in 20S proteasome lysis buffer (20 mM Tris, pH 7.5,
0.1 mM ethylenediaminetetraacetic acid, 20% glycerol, and 0.05% NP-40 supplemented each
time with fresh 1 mM β-mercaptoethanol and 1 mM adenosine triphosphate) and lysed by
freezing and thawing 3X on dry ice. Samples were centrifuged at 12,000 rpm for 1 min, and
100 µL supernatant was aliquoted into duplicate wells in a 96-well plate. Proteasome
inhibitors were added to wells at indicated concentrations and incubated for varying lengths
of time. Proteasome activity was measured by adding substrate buffer containing fluorogenic
substrates and reading fluorescence on a plate reader, as described under “Proteasome
Activity Assay.”

Viability Assessment
Cells were harvested by brief incubation with 0.05% trypsin. Cells were pelleted by
centrifugation (1,700 rpm for 3 min) and resuspended in 500 µL PBS. Viability was
measured by the ability of cells to exclude trypan blue using a Vi-CELL® (Beckman Coulter,
Inc., Pasadena, CA, USA).

Profiling of Specific Subunit Targeting by ONX-0914
The ProCISE (proteasome constitutive/immunoproteasome subunit enzyme-linked
immunosorbent) assay was performed in collaboration with Onyx Pharmaceuticals as
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previously described [142]. LN18 cells plated in 10 cm2 dishes were treated with indicated
doses of drugs in sufficient numbers to obtain 10X106 cells at the end of treatment. Cells
were then analyzed by Onyx using an active site probe to isolate active proteasome subunits,
followed by analysis with primary antibodies specific for each subunit to determine the
amount of each subunit unbound by the i-proteasome inhibitor in each sample.

Knockdown of PA28γ
Cells (1X106) were electroporated with 1 or 2 µM ON TARGET plus SMART pool
siRNA for PSME3 or the control SMART pool (Thermo Scientific Dharmacon) using an
Amaxa™ Nucleofector™ (Lonza, Basel, Switzerland). Efficiency of knockdown was
checked by Western blot. To test sensitivity to proteasome inhibitors, cells electroporated
with 2 µM siRNA were re-plated 24 h after transfection. Then, 24 h after plating, cells were
treated for 48 h with proteasome inhibitors.

Colony Assay
A base agarose layer was formed by mixing 10 mL sterile water containing 4% lowmelt agarose with 85 mL DMEM/F12 media containing 10% FBS and 15 mL additional
FBS. The base agarose (0.5 mL) was added to each well in a 24-well plate. Then, a top
agarose layer was formed by mixing 10 mL sterile water containing 3% low-melt agarose
with 42.5 mL DMEM/F12 media containing 10% FBS and 7.5 mL additional FBS. LN18
cells were added to the top agarose (1,300 cells/mL), and 0.5 mL top agarose containing cells
was added to each well of the 24-well plate on top of the base layer of agarose. After the top
matrix solidified, 300 µL warm media was added to the top of each well. Cells were grown in
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these plates for 5 days. After 5 days, proteasome inhibitors were added to the top media of
each well, and cells were incubated with the drug for 3 additional days. Wells were analyzed
using a GelCount™ machine (Oxford Optronix, Oxfordshire, England). Biomass was
calculated as the number of colonies multiplied by the average volume.

Caspase 3/7 Activity
Harvested cells were re-suspended in PBS and aliquoted to duplicate wells (50 µL per
well) of a 96-well plate on dry ice. After freezing, samples were thawed and incubated for 3
h with 150 µL DEVD buffer, pH 7.25 (100 mM HEPES, 10% sucrose, 5 mM DTT, 0.0001%
IGEPAL, 0.1% CHAPS) containing 50 µM Ac-DEVD-amc fluorogenic substrate (Enzo Life
Sciences, Farmingdale, NY, USA). Fluorescence was read on a Gemini EM Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA) at an excitation of 355 nM and an
emission of 460 nM.

Caspase 2 Venus bimolecular fluorescence complementation
Measurement of induced proximity of caspase 2 using the caspase-2 BiFC was
performed as previously described [178]. LN18 cells were plated in a 4-chamber dish
containing coverslips (Nunc, Roskilde, Denmark) 24 h prior to transfection. Cells were
transfected with caspase 2-CARD-VC (100 ng/well), caspase 2-CARD-VN (100 ng/well),
and dsRed mito (20 ng/well) using lipofectamine 2000 (Life Technologies, Carlsbad, CA,
USA). The following day, cells were treated with 290 nM MRZ or 15 nM BTZ. Cells were
imaged using a spinning disk confocal microscope (Zeiss, Jena, Germany). Temperature was
maintained at 37°C and 5% CO2 using an environmental control chamber. Zen 2012 software
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(Zeiss, Jena, Germany) was used to acquire images using a Zeiss Plan-Neofluar 40x 1.3 NA
objective on an Orca R2 CCD camera and to analyze average Venus intensity.

Transient knockdown (siRNA) of caspase 2, caspase 9, cIAP-1, and XIAP
Cells were plated at 100,000 cells per well in 6-well dishes. After 24 h, cells were
transected with siRNA against caspase 2 (L-003465-00, Thermo Scientific, both siRNA pool
and individual siRNAs were used), caspase 9 (sc-29931, Santa Cruz), cIAP-1 (sc-29848,
Santa Cruz), XIAP (sc-37508, Santa Cruz), or corresponding control siRNA pools using
Lipofectamine® RNAiMAX (Life Technologies, Carlsbad, CA, USA). Twenty-four h posttransfection, fresh media was added to each well, and cells were then treated as indicated.

Generation of cells with stable knockdown (shRNA) of caspases 2, 8, and 9
GIPZ lentiviral shRNA was obtained from GE Healthcare (Buckinghamshire,
England) with sequences targeting caspase 2 (V3LHS_338913, sequence:
CAGACATCTCCTTGCACCG), caspase 8 (V2LHS_12733, sequence:
TTCTTAGTGTGAAAGTAGG), and caspase 9 (V3LHS_412093, sequence:
TGTCGTCAATCTGGAAGCT). Lentiviral infection of LN18 cells was performed using a
Trans-Lentiviral Packaging Kit from Thermo Fisher Scientific (Waltham, MA, USA). Cells
stably expressing the shRNA were selected using puromycin.

Cytochrome C Western blots in cytoplasmic fractions
LN18 cells grown in 10 cm2 dishes were harvested by brief incubation with 0.05%
trypsin. Cells were pelleted, then washed 1X in PBS. Cells were then lysed on ice in 50–75
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µL cold STE buffer (250 mM sucrose, 1 mM EDTA, 25 mM Tris, pH 6.8) for 2–4 min, until
cells were trypan blue positive. Samples were then centrifuged at 14,000 rpm for 5 min at 4
°C. Supernatants were transferred to a new tube; pellets contained mitochondria.
Supernatants were then analyzed by Western blot for cytochrome C.

Mitochondrial membrane potential measurement
At the end of treatment, cells were harvested by brief incubation with 0.05% trypsin
and pelleted by centrifugation (1,700 rpm for 3 min). Cells were then washed 1X in PBS.
Cells were then resuspended in 1 mL PBS containing 25 nM TMRE and incubated for 30
min at 37 °C. Samples were then centrifuged (1,700 rpm for 3 min) and pellet was
resuspended in 300 µL PBS for analysis on the FL-2 channel of a flow cytometer
(FACSCalibur™, BD Biosciences, San Jose, CA, USA).

Generation of Bcl-XL overexpressing cells
Bcl-XL overexpression and pLZRS control retroviral vectors were obtained from Lisa
Bouchier-Hayes (Baylor College of Medicine). A 3-plasmid system was used to produce
retrovirus. First, 3X106 293T cells were plated in 10 cm2 plates in 10 mL DMEM containing
10% FBS, 1% penicillin and streptomycin, and 1% glutamine. The following day, the media
was changed 2–4 h before transfection. Plasmids were mixed together in tubes (12 µg pLZRS
or Bcl-XL retroviral vector, 6 µg pMD “old” Gag-pol, and 2 µg VSVG). Sterile water was
added up to 500 µL. Next, 500 µL 2X HBS buffer was added, and tubes were mixed well.
Finally, 50 µL CaCl2 solution, pH 5.5, was added, and plasmids were incubated 20–30 min at
room temperature, gently mixing and shaking periodically. The plasmid mix was then added
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to the 293T cells, and cells were incubated overnight at 37 °C. After harvesting virus and
changing media 3 times, pooled virus was filtered through a 0.45 micron filter. Filtered virus
(1.5–2 mL) was added to target cells (LN18) with 8 µg/mL polybrene for 1–2 h. Fresh media
was added to wells for overnight incubation. Cells were selected for stable expression using
zeocin.

Reactive oxygen species detection
Hydroethidium staining for superoxides
Treated samples were centrifuged for 3 min at 1,700 rpm to pellet cells. Cells were
resuspended in 1 mL PBS containing 10 µM hydroethidium dye. After 30 min incubation at
37 °C, samples were pelleted (3 min at 1,700 rpm) and resuspended in 300 µL PBS for
analysis on the FL-3 channel of a flow cytometer (FACSCalibur™, BD Biosciences, San
Jose, CA, USA).

CM-H2DCFDA staining for hydrogen peroxide
Treated samples were centrifuged for 3 min at 1,700 rpm to pellet cells. Cells were
resuspended in 1 mL DMEM/F12 media containing 10 µM CM-H2DCFDA and incubated for
30 min at 37 °C. Then, samples were washed 1X in PBS and resuspended in 300 µL PBS for
analysis on the FL-1 channel of a flow cytometer (FACSCalibur™, BD Biosciences, San
Jose, CA, USA).

Measurement of glutathione levels
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Cells were harvested by brief incubation with 0.05% trypsin, followed by
centrifugation (1,700 rpm for 3 min) and 1X wash in PBS. Cells were resuspended in 1 mL
PBS and 2 µL monochlorobimane solution (2.2 mg monochlorobimane in 194.12 µL
acetonitrile) was added to each sample. Samples were vortexed and incubated at 37 °C for 15
min. The reaction was halted by adding 50 µL trichloroacetic acid and vortexing. Samples
were spun for 5 min at 10,000 rpm, and 1 mL supernatant was added to a glass tube
containing 1 mL dichloromethane. Glass tubes were vortexed and centrifuged for 2 min at
3,500 rpm. For each sample, 200 µL of the top aqueous layer was plated in duplicate wells in
a white 96-well plate. Fluorescence was read on a Gemini EM Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA) at an excitation of 360 nM and an emission of 460 nM.
Glutathione concentrations were determined by comparing samples to a standard curve
composed of varying concentrations of glutathione ethyl ester dissolved in PBS.

Amino acid and metabolite measurement
Analysis of amino acid and metabolite levels was performed as previously described
[154] in collaboration with Preeti Purwaha, Philip Lorenzi, and David Hawke in the
Proteomics Core at MD Anderson Cancer Center. LN18 cells were treated for indicated time
periods in 10 cm2 dishes. Media was suctioned off plate, and plate was placed on dry ice.
Next, plates were washed 2X with 5 mL methanol ambic. A solution of methanol,
chloroform, and water (7:2:1) was then added to each plate (500 µL) directly to the center of
the plate. Cells were scraped using a cell scraper, and mixture was transferred to a simport
tube. Samples were shaken using a Disruptor Genie for 30 sec in a cold room, then debris
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was pelleted by spinning at 20,000 xg for 2 min. Samples were then analyzed by mass
spectrometry as described [154].

Intracranial mouse xenograft model
An intracranial guidescrew model of GBM was used, as previously described [155].
We implanted 500,000 U87 GBM cells though a guidescrew in 5-week-old female athymic
nude mice (Experimental Radiation Oncology, MD Anderson, Houston, TX) and let tumors
develop for 1–2 weeks (as noted in Results). Mice were then injected intraperitoneally with 1
mg/kg BTZ, 0.15 mg/kg MRZ, and/or 50 mg/kg vorinostat in dosing schedules outlined in
the Results. For lysates, the tumor sections were frozen in liquid nitrogen, then homogenized
by vortexing with zirconia/silica beads (Biospec, Bartlesville, OK, USA) in lysis buffer (20
mM Tris, pH 7.5, 0.1 mM EDTA, 20% glycerol, and 0.05% NP-40). For IHC analysis,
samples were preserved in formalin, then paraffin-embedded.

Immunohistochemistry
Slides were deparaffinized and hydrated in xylene and graded ethanol solutions.
Endogenous peroxidase activity was blocked with 3% H2O2 in water for 10 min. Slides were
washed, then antigen retrieval was performed using 1.0 mM EDTA buffer, pH 8.0 (for p21)
or 10 mM citrate buffer, pH 6.0 (for cleaved caspase 3 and lamin A) in a microwave (3 min
at 100% power, 10–15 min at 50% power). After cooling and washing in water, slides were
incubated with blocking reagent (Biocare, Concord, CA) for 10 min. Slides were then
incubated with antibodies for p21 (sc-6246, 1:50 dilution: Santa Cruz, Dallas, TX), cleaved
caspase 3 (AF835, 1:500 dilution: R&D Systems, Minneapolis, MN), or cleaved lamin A
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(2035, 1:100 dilution: Cell Signaling, Beverly, MA) overnight at 4 °C. Slides were then
washed and incubated with secondary antibody (for p21: biotinylated rabbit-anti mouse for
15 min, [Accurate Chem, Westbury, NY]; for cleaved caspase 3: biotinylated goat-anti-rabbit
for 30 min [Vector Laboratories, Burlingame, CA]; for lamin A: anti-rabbit horseradish
peroxidase for 30 min [Dako, Glostrup, Denmark]). Slides were then incubated with Tablet
DAB (for p21 and cleaved caspase 3; Sigma, St. Louis, MO) or Dako (Glostrup, Denmark)
DAB. Slides were washed, counterstained with hematoxylin, dehydrated, and coverslipped.
Slides were visualized and the number of positive cells per 40X was counted and averaged
for 5 fields.

Analysis of acetylated and total histone levels
Cells were pelleted by centrifugation (1,700 rpm for 3 min) and washed 1X with PBS. Pellets
were resuspended in 100 µL Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X100 and 0.02% NaN3, with freshly added 2 mM PMSF and 5 mM sodium butyrate) and lysed
on ice for 10 min with gentle stirring. Samples were centrifuged at 6,500 xg for 10 min at 4
°C to pellet nuclei. Supernatant was discarded, and nuclei were washed with 50 µL TEB and
pelleted as before. Pellets were then resuspended in 40 µL 0.2 N HCl, and histones were acid
extracted overnight at 4 °C. Samples were centrifuged at 6,500 xg for 10 min at 4 °C to pellet
debris, and supernatants containing histones were analyzed by Western blot.

Measurement of PSMB5 mRNA
RNA was isolated using an RNeasy Mini Kit (Qiagen, Limburg, Netherlands). The
concentration of RNA was determined using a Nanodrop (Thermo Scientific, Waltham, MA),

156

and equal amounts of RNA were used for reverse transcription to cDNA using an Omniscript
RT Kit (Qiagen). PSMB5 and actin levels were then assessed by mixing cDNA with SYBR
green (Bio Rad, Hercules, CA) and primers (PSMB5 primers: forward, 5’TAAGGAACGCATCTCTGTAGCA; reverse, 5’-TCCACTTCCAGGTCATAGGAAT-3’;
actin primers: forward, 5’-CTGTGGCATCCACGAAACTA-3’; reverse, 5’CGCTCAGGAGGAGCAATG-3’) and measuring amplification on an iCycler qPCR
machine (Bio Rad). Amplification was performed using the following qPCR protocol: initial
temperature of 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 seconds and 63 °C
for 1 min, followed by 95 °C for 1 min, then a hold at 55 °C.

Statistical analysis
Values are given as the mean ± standard error of the mean, with all experiments
performed at least in triplicate. Comparisons were made using Student’s t tests performed
using GraphPad Prism software, version 6 (GraphPad software, La Jolla, CA, USA). Pvalues < 0.05 were considered significant. Synergy was determined with the method
described by Chou and Talalay [158] using CalcuSyn software (Biosoft, Cambridge, United
Kingdom), with combination index (CI) values < 1 being considered synergistic.
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